J. Verweij

发表

[New guidelines to evaluate the response to treatment in solid tumors].

M. Christian, E. Eisenhauer, L. Rubinstein, 2000, Bulletin du cancer.

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

L. Schwartz, D. Sargent, L. Dodd, 2009, European journal of cancer.

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.

J. Blay, M. van Glabbeke, A. Hagemeijer, 2006, European journal of cancer.

32 INVITED New response evaluation criteria in solid tumors: revised RECIST guideline version 1.1

L. Schwartz, D. Sargent, D. Lacombe, 2008 .

The kinase RSK2 modulates the sensitivity of ovarian cancer cells to cisplatin.

Marijn T. M. van Jaarsveld, A. W. Boersma, E. Wiemer, 2013, European Journal of Cancer.

Validated bioanalytical method for the quantification of RGB-286638, a novel multi-targeted protein kinase inhibitor, in human plasma and urine by liquid chromatography/tandem triple-quadrupole mass spectrometry.

E. Wiemer, J. Verweij, P. de Bruijn, 2009, Journal of Pharmaceutical and Biomedical Analysis.

Leveling the Playing Field: Bringing Development of Biomarkers and Molecular Diagnostics up to the Standards for Drug Development

D. Carbone, J. Verweij, S. Hewitt, 2012, Clinical Cancer Research.

New guidelines to evaluate the response to treatment in solid tumors

M. van Glabbeke, M. Christian, E. Eisenhauer, 2000, Journal of the National Cancer Institute.

Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study.

Peter Wust, Ulrich Mansmann, Peter Hohenberger, 2010, The Lancet. Oncology.

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

M Van Glabbeke, J Verweij, M. van Glabbeke, 2000, Journal of the National Cancer Institute.

Sensitive high-performance liquid chromatographic fluorescence assay for the quantitation of topotecan (SKF 104864-A) and its lactone ring-opened product (hydroxy acid) in human plasma and urine.

J. Verweij, J. Schellens, W. Loos, 1996, Journal of chromatography. B, Biomedical applications.

A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours

B. Reigner, J. Verweij, P. Vasey, 2000, British Journal of Cancer.

Determination of the docetaxel vehicle, polysorbate 80, in patient samples by liquid chromatography-tandem mass spectrometry.

J. Verweij, S. Baker, A. Sparreboom, 2002, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up.

S. Sleijfer, J. Verweij, P. Casali, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

RECIST revisited: a review of validation studies on tumour assessment.

E. Eisenhauer, P. Therasse, J. Verweij, 2006, European journal of cancer.

Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: results of a DLT-TARGETT international survey.

Percy Ivy, Xavier Paoletti, Laurence Collette, 2014, European journal of cancer.

Disposition of docetaxel in the presence of P-glycoprotein inhibition by intravenous administration of R101933.

J. Verweij, L. van Zuylen, A. Sparreboom, 2002, European journal of cancer.

CHAPTER 18 – CLINICAL TRIAL DESIGN: INCORPORATION OF PHARMACOKINETIC, PHARMACODYNAMIC, AND PHARMACOGENETIC PRINCIPLES

J. Verweij, A. Sparreboom, W. Loos, 2002 .

Limited sampling models for topotecan pharmacokinetics.

J. Verweij, H. Rosing, J. Beijnen, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

O6‐Methylguanine‐DNA Methyltransferase (MGMT) as a Determinant of Resistance to Camptothecin Derivatives

J. Verweij, H. Takano, K. Tanimoto, 2002, Japanese journal of cancer research : Gann.

(Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor.

S. Sleijfer, J. Verweij, P. Hamberg, 2010, The oncologist.

Ecteinascidin-743 (ET-743): early test or effective treatment in soft tissue sarcomas?

J. Verweij, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II studies of Elsamitrucin in breast cancer, colorectal cancer, non-small cell lung cancer and ovarian cancer. EORTC Early Clinical Trials Group.

M. Piccart, J. Wanders, J. Verweij, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib

S. Bates, J. Verweij, A. Oosterom, 2006, Clinical pharmacology and therapeutics.

Irinotecan pathway genotype analysis to predict pharmacokinetics.

Sharon Marsh, Ron H J Mathijssen, Mats O Karlsson, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Irinotecan Pathway Genotype Analysis to Predict Pharmacokinetics 1

H. McLeod, J. Verweij, S. Marsh, 2003 .

Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation.

J Verweij, J. Verweij, H. Gelderblom, 2001, European journal of cancer.

Immunotherapy of metastatic renal cell cancer.

J. Verweij, G. Stoter, S. H. Goey, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

The role of CA 125 in the early diagnosis of progressive disease in ovarian cancer.

J. Verweij, F. Lammes, M. V. D. Van Der Burg, 1990, Annals of oncology : official journal of the European Society for Medical Oncology.

CA 125 in ovarian cancer.

J. Verweij, F. Lammes, M. V. D. Van Der Burg, 1992, The Netherlands journal of medicine.

The role of CA 125 and conventional examinations in diagnosing progressive carcinoma of the ovary.

J. Verweij, F. Lammes, M. V. D. Van Der Burg, 1993, Surgery, gynecology & obstetrics.

Topoisomerase I inhibitors: topotecan and irenotecan.

J. Verweij, G. Creemers, B. Lund, 1994, Cancer treatment reviews.

Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors.

M. J. van den Bent, J. Verweij, J. Schellens, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Farnesyl transferase inhibitors: current developments and future perspectives.

J. Verweij, G. Stoter, F. Eskens, 2000, Cancer treatment reviews.

Effects of CYP Induction by Rifampicin on Tamoxifen Exposure

A. Jager, C. Seynaeve, J. Verweij, 2012, Clinical pharmacology and therapeutics.

Liquid chromatographic determination of irinotecan and three major metabolites in human plasma, urine and feces.

J. Verweij, A. Sparreboom, P. de Bruijn, 1998, Journal of chromatography. B, Biomedical sciences and applications.

A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation

A. Tolcher, J. Verweij, P. LoRusso, 2021, Clinical Cancer Research.

Clinical Pharmacokinetics of Docetaxel

J. Verweij, S. Baker, A. Sparreboom, 2006, Clinical pharmacokinetics.

Disposition of polyoxyethylated excipients in humans: Implications for drug safety and formulation approaches

J. Verweij, S. Baker, A. Sparreboom, 2003, Clinical pharmacology and therapeutics.

Clinical pharmacokinetics of unbound docetaxel: Role of polysorbate 80 and serum proteins

J. Verweij, S. Baker, A. Sparreboom, 2003, Clinical pharmacology and therapeutics.

Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo.

J. Verweij, A. Sparreboom, W. Loos, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

ABCG2 Pharmacogenetics

H. McLeod, J. Verweij, S. Marsh, 2004, Clinical Cancer Research.

A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors

P. Sonneveld, P. Sonneveld, J. Verweij, 2004, Cancer Chemotherapy and Pharmacology.

Determination of doxorubicin and doxorubicinol in plasma of cancer patients by high-performance liquid chromatography.

J. Verweij, A. Sparreboom, P. de Bruijn, 1999, Analytical Biochemistry.

Docetaxel administration schedule: from fever to tears? A review of randomised studies.

J. Verweij, F. Engels, 2005, European journal of cancer.

Mechanism-based pharmacokinetic model for paclitaxel.

M O Karlsson, J Verweij, J. Verweij, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Pharmacogenetic Predictive Model for Paclitaxel Clearance Based on the DMET Platform

M. Smid, E. Wiemer, J. Martens, 2013, Clinical Cancer Research.

Predictive Biomarkers and Personalized Medicine CYP 3 A 4 22 Genotype and Systemic Exposure Affect Paclitaxel-Induced Neurotoxicity

E. Wiemer, J. Verweij, A. Sparreboom, 2013 .

Variants in the SLCO1B3 Gene: Interethnic Distribution and Association with Paclitaxel Pharmacokinetics

H. McLeod, J. Verweij, S. Marsh, 2007, Clinical pharmacology and therapeutics.

Effect of valspodar on the pharmacokinetics of unbound paclitaxel

J. Doroshow, J. Verweij, D. Spicer, 2003, Investigational New Drugs.

Real-time pharmacokinetics guiding clinical decisions; phase I study of a weekly schedule of liposome encapsulated paclitaxel in patients with solid tumours.

J. Verweij, A. Sparreboom, M. D. de Jonge, 2004, European journal of cancer.

Disposition of docosahexaenoic acid-paclitaxel, a novel taxane, in blood: in vitro and clinical pharmacokinetic studies.

A. Wolff, J. Verweij, R. Donehower, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Randomized C ross-Over E valuation o f B ody-Surface Area-Based D osing V ersus F lat-Fixed D osing o f P aclitaxel

J. Verweij, A. Sparreboom, M. Bontenbal, 2003 .

Pharmacological Effects of Formulation Vehicles

J. Verweij, A. Sparreboom, W. Loos, 2003, Clinical pharmacokinetics.

Altered clearance of unbound paclitaxel in elderly patients with metastatic breast cancer.

C. Seynaeve, J. Verweij, A. Sparreboom, 2003, European journal of cancer.

Distribution of paclitaxel in plasma and cerebrospinal fluid

J. Verweij, H. Gelderblom, S. Baker, 2003, Anti-Cancer Drugs.

Randomized cross-over evaluation of body-surface area-based dosing versus flat-fixed dosing of paclitaxel.

J. Verweij, A. Sparreboom, M. Bontenbal, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Paclitaxel pharmacokinetics, threshold models, and dosing strategies.

J. Verweij, A. Sparreboom, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel.

J. Verweij, H. Gelderblom, A. Sparreboom, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001.

L. Grochow, J. Verweij, J. Schellens, 2002, Journal of the National Cancer Institute.

Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions.

J. Verweij, H. Gelderblom, A. Sparreboom, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparative P harmacokinetics o f U nbound P aclitaxel During 1 - a nd 3 -Hour I nfusions

J. Verweij, H. Gelderblom, A. Sparreboom, 2002 .

Determination of paclitaxel in human plasma using single solvent extraction prior to isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection.

J. Verweij, A. Sparreboom, P. de Bruijn, 1998, Journal of chromatography. B, Biomedical sciences and applications.

Linearized colorimetric assay for cremophor EL: application to pharmacokinetics after 1-hour paclitaxel infusions.

J. Verweij, A. Sparreboom, W. Loos, 1998, Analytical biochemistry.

Quantitation of Cremophor EL in human plasma samples using a colorimetric dye-binding microassay.

J. Verweij, A. Sparreboom, W. Loos, 1998, Analytical biochemistry.

Rapid esterase-sensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokinetics of docetaxel and metabolites in mice.

J. Verweij, J. Beijnen, A. Sparreboom, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Measurement of fraction unbound paclitaxel in human plasma.

J. Verweij, A. Sparreboom, P. de Bruijn, 2000, Drug metabolism and disposition: the biological fate of chemicals.

Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).

J Verweij, J. Verweij, A. Sparreboom, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Renal Function as a Predictor of Irinotecan‐induced Neutropenia

J. Verweij, A. Sparreboom, R. Mathijssen, 2008, Clinical pharmacology and therapeutics.

Irinotecan chemotherapy during valproic acid treatment: Pharmacokinetic interaction and hepatotoxicity

M. J. van den Bent, J. Verweij, R. Mathijssen, 2007, Cancer biology & therapy.

Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study.

J. Verweij, A. Sparreboom, R. Mathijssen, 2006, The oncologist.

Role of pharmacogenetics in irinotecan therapy.

J. Verweij, R. Mathijssen, M. D. de Jonge, 2006, Cancer letters.

Phase I Pharmacokinetic, Food Effect, and Pharmacogenetic Study of Oral Irinotecan Given as Semisolid Matrix Capsules in Patients with Solid Tumors

J. Verweij, A. V. van Oosterom, A. Sparreboom, 2005, Clinical Cancer Research.

Limited Potential of Hepatic Arterial Infusion of Irinotecan

J. Verweij, R. Mathijssen, F. D. de Jong, 2004, Journal of chemotherapy.

Indirect determination of the irinotecan metabolite 7-ethyl-10-O-glucuronyl-camptothecin in human samples.

J. Verweij, A. Sparreboom, P. de Bruijn, 2004, Analytical biochemistry.

ABCG2 Pharmacogenetics: Ethnic Differences in Allele Frequency and Assessment of Influence on Irinotecan Disposition

H. McLeod, J. Verweij, S. Marsh, 2004 .

Phase I and pharmacokinetic study of irinotecan in combination with R115777, a farnesyl protein transferase inhibitor

J. Verweij, A. Sparreboom, P. de Bruijn, 2004, British Journal of Cancer.

Flat-Fixed Dosing of Irinotecan

J. Verweij, A. Sparreboom, R. Mathijssen, 2004, Clinical Cancer Research.

Determination of irinotecan (CPT-11) and SN-38 in human whole blood and red blood cells by liquid chromatography with fluorescence detection.

J. Verweij, A. Sparreboom, R. Mathijssen, 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis.

J. Verweij, M. Karlsson, A. Sparreboom, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact o f B ody-Size M easures o n I rinotecan C learance: Alternative D osing R ecommendations

J. Verweij, A. Sparreboom, G. Stoter, 2002 .

Irinotecan pharmacokinetics-pharmacodynamics: the clinical relevance of prolonged exposure to SN-38

J. Verweij, A. Sparreboom, P. de Bruijn, 2002, British Journal of Cancer.

Impact of body-size measures on irinotecan clearance: alternative dosing recommendations.

J. Verweij, A. Sparreboom, R. Mathijssen, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea

J. Verweij, M. Karlsson, A. Sparreboom, 2002, Clinical pharmacology and therapeutics.

Determination of the lactone and lactone plus carboxylate forms of 9-aminocamptothecin in human plasma by sensitive high-performance liquid chromatography with fluorescence detection.

J. Verweij, J. Schellens, A. Sparreboom, 1997, Journal of Chromatography B: Biomedical Sciences and Applications.

Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development.

J. Verweij, M. D. de Jonge, J. Schellens, 1997, British Journal of Cancer.

Irinotecan (CPT-11) metabolism and disposition in cancer patients.

J. Verweij, A. Sparreboom, P. de Bruijn, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Role of erythrocytes and serum proteins in the kinetic profile of total 9-amino-20(S)-camptothecin in humans.

J. Verweij, H. Gelderblom, A. Sparreboom, 1999, Anti-cancer drugs.

Sparse-data set analysis for irinotecan and SN-38 pharmacokinetics in cancer patients co-treated with cisplatin.

J. Verweij, A. Sparreboom, P. de Bruijn, 1999, Anti-cancer drugs.

Drug-administration sequence does not change pharmacodynamics and kinetics of irinotecan and cisplatin.

J. Verweij, A. Sparreboom, P. de Bruijn, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Factors involved in prolongation of the terminal disposition phase of SN-38: clinical and experimental studies.

J. Verweij, A. Sparreboom, P. de Bruijn, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I study of 3-week schedule of irinotecan combined with cisplatin in patients with advanced solid tumors.

J. Verweij, A. Sparreboom, M. D. de Jonge, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacokinetic, metabolic, and pharmacodynamic profiles in a dose-escalating study of irinotecan and cisplatin.

J. Verweij, A. Sparreboom, P. de Bruijn, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients.

J. Verweij, A. Sparreboom, P. de Bruijn, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Metastatic Soft Tissue Sarcoma in Adults

O. S. Nielsen, J. Blay, J. Verweij, 2003 .

Renal toxicities of chemotherapy.

J. Verweij, M. D. de Jonge, 2006, Seminars in Oncology.

Docetaxel (Taxotere®): An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck

M. Piccart, J. Wanders, J. Verweij, 1994 .

Limited sampling model for area under the concentration time curve of total topotecan.

M. Ratain, J. Verweij, J. Beijnen, 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I drug combination trial design: walking the tightrope.

J. Verweij, P. Hamberg, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combination chemotherapy of the taxanes and antimetabolites: its use and limitations.

J. Verweij, A. Sparreboom, M. Bontenbal, 2001, European journal of cancer.

Achievements and future of chemotherapy.

J. Verweij, M. D. de Jonge, M. Jonge, 2000, European journal of cancer.

Soft Tissue Sarcomas: Present Achievements and Future Prospects

J. Verweij, H. Suit, H. Pinedo, 1997, Cancer treatment and research.

Adaptive intrapatient dose escalation of cisplatin in combination with low-dose vp16 in patients with nonsmall cell lung cancer

M. J. van den Bent, J. Verweij, J. Schellens, 2003, British Journal of Cancer.

A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours

J. Verweij, E. de Vries, J. Gietema, 2007, British Journal of Cancer.

The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomas.

S. Sleijfer, C. Seynaeve, J. Verweij, 2007, The oncologist.

The reason for confining the use of adjuvant chemotherapy in soft tissue sarcoma to the investigational setting.

C. Seynaeve, J. Verweij, 1999, Seminars in radiation oncology.

The treatment of soft tissue sarcomas with focus on chemotherapy: a review.

J. Verweij, H. Pinedo, 1986, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Docetaxel (Taxotere): single agent activity, development of combination treatment and reducing side-effects.

J. Verweij, G. Stoter, L. Pronk, 1995, Cancer treatment reviews.

A randomized phase II study with two schedules of the novel indoloquinone EO9 in non-small-cell lung cancer: a study of the EORTC Early Clinical Studies Group (ECSG).

A. te Velde, J. Verweij, J. Smyth, 1996, Annals of Oncology.

Peripheral neurotoxicity induced by docetaxel

M. J. van den Bent, J. Verweij, W. van Putten, 1996, Neurology.

Gynaecological sarcomas

S. Sleijfer, C. Seynaeve, J. Verweij, 2007, Current opinion in oncology.

4β-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes.

E. Wiemer, J. Verweij, E. de Jonge, 2015, British journal of clinical pharmacology.

Principles and Examples of Cancer (Cell) Specific Therapies

J. Verweij, F. Eskens, 2009 .

Mitomycin C.

J. Verweij, H. Pinedo, 1990, Cancer chemotherapy and biological response modifiers.

Simultaneous analysis of docetaxel and the formulation vehicle polysorbate 80 in human plasma by liquid chromatography/tandem mass spectrometry.

J. Verweij, M. Carducci, S. Baker, 2004, Analytical Biochemistry.

Clinical studies in the development of new anticancer agents exhibiting growth inhibition in models: facing the challenge of a proper study design.

J. Verweij, F. Eskens, 2000, Critical reviews in oncology/hematology.

Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group.

O. S. Nielsen, J. Blay, M. van Glabbeke, 2002, European journal of cancer.

Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel

J. Verweij, W. Loos, R. V. van Schaik, 2006, Cancer biology & therapy.

Adjuvant chemotherapy of soft tissue sarcomas.

J. Verweij, H. Pinedo, J. Verweij, 1997, Cancer treatment and research.

The present state of the art in chemotherapy for soft tissue sarcomas in adults: the EORTC point of view.

M. van Glabbeke, J. Verweij, M. Glabbeke, 1995, Critical reviews in oncology/hematology.

Chemotherapy in the multidisciplinary approach to soft tissue sarcomas. EORTC Soft Tissue and Bone Sarcoma Group studies in perspective.

J. Verweij, A. Santoro, A. V. van Oosterom, 1992, Annals of Oncology.

Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese.

A. Wolff, J. Verweij, S. Baker, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Influence of Smoking on the Pharmacokinetics and Toxicity Profiles of Taxane Therapy

E. Wiemer, J. Verweij, B. van der Holt, 2012, Clinical Cancer Research.

Phase I and Pharmacokinetic Study of the Polyamine Synthesis Inhibitor SAM 486 A in Combination with 5-Fluorouracil / Leucovorin in Metastatic Colorectal Cancer

J. Ledermann, J. Verweij, J. Bridgewater, 2004 .

Phase I and Pharmacokinetic Study of the Polyamine Synthesis Inhibitor SAM486A in Combination with 5-Fluorouracil/ Leucovorin in Metastatic Colorectal Cancer

J. Ledermann, J. Verweij, L. van Zuylen, 2004, Clinical Cancer Research.

Capecitabine, a n O ral F luoropyrimidine C arbamate W ith Substantial A ctivity i n A dvanced C olorectal C ancer: Results o f a R andomized P hase I I S tudy

J. Verweij, R. Pazdur, L. Dirix, 2000 .

Phase I study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with 5-fluorouracil and leucovorin: a safe combination.

E. D. de Vries, J. Verweij, J. Gietema, 2006, European journal of cancer.

Pitfalls of the application of microdialysis in clinical oncology: controversial findings with docetaxel.

J. Verweij, P. de Bruijn, M. Lam, 2007, Journal of pharmaceutical and biomedical analysis.

Phase II study of weekly high-dose cisplatin for six cycles in patients with locally advanced squamous cell carcinoma of the head and neck.

J. Verweij, P. D. De Mulder, A. de Graeff, 1997, European journal of cancer.

Phase II studies of docetaxel in the treatment of various solid tumours. EORTC Early Clinical Trials Group and the EORTC Soft Tissue and Bone Sarcoma Group.

S. Aamdal, J. Verweij, C. Sternberg, 1995, European journal of cancer.

Effects of mannose-binding lectin polymorphisms on irinotecan-induced febrile neutropenia.

S. Sleijfer, J. Verweij, A. Sparreboom, 2010, The oncologist.

Phase I S tudy o f 3 -Week S chedule o f I rinotecan Combined W ith C isplatin i n P atients W ith A dvanced Solid T umors

J. Verweij, A. Sparreboom, C. Jacques, 2000 .

Low Dose Methotrexate and Vinblastine, Given Weekly to Patients With Desmoid Tumours, is Associated With Major Toxicity

C. Seynaeve, J. Verweij, B. V. van Geel, 2003, Sarcoma.

Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies

S. Sleijfer, J. Verweij, H. Gelderblom, 2010, British Journal of Cancer.

Irinotecan‐induced Diarrhea: Functional Significance of the Polymorphic ABCC2 Transporter Protein

J. Verweij, D. Kroetz, S. Marsh, 2007, Clinical pharmacology and therapeutics.

Effect of ABCG2 genotype on the oral vioavailability of topotecan

J. Verweij, H. Gelderblom, A. Sparreboom, 2005, Cancer biology & therapy.

Effect of omeprazole on the pharmacokinetics and toxicities of irinotecan in cancer patients: a prospective cross-over drug-drug interaction study.

E. Wiemer, J. Verweij, R. Mathijssen, 2011, European Journal of Cancer.

Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor.

J. Verweij, H. Rosing, J. Beijnen, 1996, British Journal of Cancer.

Pharmacogenetic Pathway Analysis of Docetaxel Elimination

A. Wolff, J. Verweij, S. Marsh, 2009, Clinical pharmacology and therapeutics.

Determination of midazolam in human plasma by liquid chromatography with mass-spectrometric detection.

J. Verweij, A. Sparreboom, W. Figg, 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Results of plasma N-terminal pro B-type natriuretic peptide and cardiac troponin monitoring in GIST patients do not support the existence of imatinib-induced cardiotoxicity.

J. Verweij, B. Rikhof, J. Gietema, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy.

A. Wolff, J. Verweij, S. Baker, 2004, European journal of cancer.

Application of prolonged microdialysis sampling in carboplatin-treated cancer patients

S. Sleijfer, E. Wiemer, J. Verweij, 2008, Cancer Chemotherapy and Pharmacology.

A multicentre phase I and pharmacokinetic study of BN80915 (diflomotecan) administered daily as a 20-min intravenous infusion for 5 days every 3 weeks to patients with advanced solid tumours.

R. Obach, J. Verweij, C. Twelves, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Prediction of the systemic exposure to oral 9-amino-20(S)-camptothecin using single-sample analysis.

J. Verweij, C. Punt, A. Sparreboom, 1999, Drug metabolism and disposition: the biological fate of chemicals.

Emerging Drug Treatments for Solid Tumours

J. Verweij, J. Schellens, L. Pronk, 2012, Drugs.

Modulation of camptothecin analogs in the treatment of cancer: a review

J. Verweij, A. Sparreboom, W. Loos, 2001, Anti-cancer drugs.

Moving the Frontiers of Cancer Chemotherapy for Solid Tumors by Changing the Scope of Drug Development.

J. Verweij, M. D. de Jonge, 1996, Hematology.

New promising anticancer agents in development: what comes next?

J. Verweij, 1996, Cancer Chemotherapy and Pharmacology.

The development of combination therapy involving camptothecins: a review of preclinical and early clinical studies.

J. Verweij, A. Sparreboom, M. D. de Jonge, 1998, Cancer Treatment Reviews.

Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study.

M. Gore, J. Verweij, G. Creemers, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor.

H. Hansen, J. Verweij, H. Rosing, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Tr

S. Sleijfer, J. Blay, S. Litière, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dose–Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study

R. Plummer, J. Verweij, J. Schellens, 2014, Clinical Cancer Research.

Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors.

R. Plummer, J. Verweij, J. Schellens, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Early Clinical Trials with Cytotoxic Agents

J. Verweij, M. D. Jonge, 2011 .

Biologic and Clinical Activity of Tivozanib (AV-951, KRN-951), a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4-Week-On, 2-Week-Off Schedule in Patients with Advanced Solid Tumors

M. Cotreau, J. Verweij, M. Thomeer, 2011, Clinical Cancer Research.

A Phase Ib dose-escalation study to evaluate safety and tolerability of the addition of the aminopeptidase inhibitor tosedostat (CHR-2797) to paclitaxel in patients with advanced solid tumours

J. Verweij, M. D. de Jonge, E. Bone, 2010, British Journal of Cancer.

Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation.

E. Wiemer, J. Verweij, H. Gelderblom, 2010, European journal of cancer.

Outcomes of First-Line Chemotherapy in Patients with Advanced or Metastatic Leiomyosarcoma of Uterine and Non-Uterine Origin

S. Sleijfer, C. Seynaeve, J. Verweij, 2009, Sarcoma.

Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial.

J. Blay, M. van Glabbeke, R. Sciot, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Other endpoints in screening studies for soft tissue sarcomas.

J. Verweij, 2008, The Oncologist.

The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitor.

J. Verweij, J. Schellens, A. Planting, 1997, British Journal of Cancer.

Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer

J. Verweij, W. van Putten, R. de Wit, 2002, British Journal of Cancer.

Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors.

M. Piccart, J. Verweij, A. Sparreboom, 2001, Journal of Clinical Oncology.

Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.

J. Verweij, J. Schellens, D. V. Von Hoff, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Five days of oral topotecan (Hycamtin), a phase I and pharmacological study in adult patients with solid tumours.

J. Verweij, J. Schellens, D. V. Von Hoff, 1998, European journal of cancer.

A phase II study of weekly high-dose cisplatin combined with oral etoposide in advanced non-small-cell lung cancer

M. J. van den Bent, J. Verweij, J. Schellens, 1997, Cancer Chemotherapy and Pharmacology.

Phase I study of intravenous fosquidone (GR63178A-NSC D611615) using a three times a week schedule.

J. Verweij, G. Stoter, M. V. D. Van Der Burg, 1992, Clinics in oncology.

Combination of IL-21 and IL-15 enhances tumour-specific cytotoxicity and cytokine production of TCR-transduced primary T cells

J. Verweij, T. Hagen, R. Debets, 2010, Cancer Immunology, Immunotherapy.

What is the role of dose-dense therapy?

J. Verweij, I. Vergote, H. V. van Doorn, 2005, International Journal of Gynecologic Cancer.

What is the role of dose-dense therapy?

J. Verweij, I. Vergote, H. V. van Doorn, 2005, International Journal of Gynecologic Cancer.

The potential of statins as part of anti-cancer treatment.

S. Sleijfer, J. Verweij, A. van der Gaast, 2005, European journal of cancer.

Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors.

M. Piccart, J. Verweij, A. Sparreboom, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical Trial Design for Target Specific Anticancer Agents

J. Verweij, R. Hoekstra, F. Eskens, 2003, Investigational New Drugs.

Pharmacogenetics of tipifarnib (R115777) transport and metabolism in cancer patients

H. McLeod, J. Verweij, S. Marsh, 2004, Investigational New Drugs.

Phase 1 study with BIBW 2992, an irreversible dual tyrosine kinase inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) in a 2 week on 2 week off schedule.

E. D. de Vries, J. Verweij, M. D. de Jonge, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Selection of large and objectively measurable target lesions in EORTC phase II trials: impact on recruitment and response rate. EORTC Soft Tissue and Bone Sarcoma Group (STBSG).

M. van Glabbeke, J. Verweij, H. Mouridsen, 1993, European journal of cancer.

Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly.

J. Verweij, M. Carducci, W. Graveland, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Weekly paclitaxel as first-line chemotherapy for elderly patients with metastatic breast cancer. A multicentre phase II trial.

C. Seynaeve, J. Verweij, A. Sparreboom, 2004, European journal of cancer.

Experience with ifosfamide in the EORTC Soft Tissue and Bone Sarcoma Group.

J. Verweij, H. Mouridsen, A. V. van Oosterom, 1992, Seminars in oncology.

Multitarget tyrosine kinase inhibition: [and the winner is...].

J. Verweij, M. D. de Jonge, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Differential modulation of cisplatin accumulation in leukocytes and tumor cell lines by the paclitaxel vehicle Cremophor EL.

J. Verweij, A. Sparreboom, P. de Bruijn, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

A prospective study on the dose dependency of cardiotoxicity induced by mitomycin C

J. Verweij, G. Teule, H. Pinedo, 1988, Medical oncology and tumor pharmacotherapy.

Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics

R. Paridaens, A. Jager, J. Verweij, 2019, Breast Cancer Research and Treatment.

Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours.

J. Verweij, A. V. van Oosterom, J. Drevs, 2003, European journal of cancer.

Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer.

M. Piccart, M. Gore, J. Wanders, 1995, Journal of the National Cancer Institute.

Radiologist review versus group peer review of claimed responses in a phase II study on high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the EORTC Soft Tissue and Bone Sarcoma Group

O. S. Nielsen, M. van Glabbeke, S. Gwyther, 2000, Anti-cancer drugs.

Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind.

J. Verweij, M. Clavel, B. Chevalier, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer. EORTC Head and Neck Cooperative Group.

J. Verweij, P. D. De Mulder, W. Oster, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Dose-response relationship in phase I clinical trials: A European Drug Development Network (EDDN) collaboration study.

R. Plummer, J. Verweij, J. Schellens, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Liquid chromatographic analysis and preliminary pharmacokinetics of methotrexate in cancer patients co-treated with docetaxel.

J. Verweij, A. Sparreboom, W. Loos, 1999, Journal of Chromatography B: Biomedical Sciences and Applications.

A phase II study of M-azido-pyrimethamine ethane sulphonate (MZPES) in advanced, recurrent soft tissue sarcoma. An EORTC Soft Tissue and Bone Sarcoma Group Study.

H. Keizer, J. Verweij, R. Sylvester, 1989, European journal of cancer & clinical oncology.

Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks

J. Verweij, J. Schellens, H. Rosing, 1995, Cancer Chemotherapy and Pharmacology.

Abrogated energy-dependent uptake of cisplatin in a cisplatin-resistant subline of the human ovarian cancer cell line IGROV-1

J. Verweij, J. Schellens, M. Maliepaard, 1997, Cancer Chemotherapy and Pharmacology.

Controlling cancer chemotherapy-induced emesis

C. Seynaeve, J. Verweij, R. Gralla, 1991, Pharmaceutisch Weekblad.

Mitomycin C-induced hemolytic uremic syndrome. Six case reports and review of the literature on renal, pulmonary and cardiac side effects of the drug.

J. Verweij, H. Pinedo, M. V. D. Van Der Burg, 1987, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment.

C. Seynaeve, J. Verweij, J. Beijnen, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Determination of 5-fluorouracil in microvolumes of human plasma by solvent extraction and high-performance liquid chromatography.

J. Verweij, L. van Zuylen, A. Sparreboom, 1999, Journal of chromatography. B, Biomedical sciences and applications.

The prognosis of prognostic factors in phase I clinical trials.

J. Verweij, 2000, Annals of Oncology.

Multidisciplinary Treatment of Soft Tissue Sarcomas

J. Verweij, H. Suit, H. Pinedo, 1993, Cancer treatment and research.

[Breast cancer in the early stage].

R. J. Jones, M. Espié, G. Giaccone, 2012, Gan no rinsho. Japan journal of cancer clinics.

Phase II study of mitozolomide in advanced soft tissue sarcoma of adults: the EORTC Soft Tissue and Bone Sarcoma Group.

C. Seynaeve, J. Verweij, A. Santoro, 1992, European Journal of Cancer.

Potential for improvement of docetaxel-based chemotherapy: a pharmacological review

J. Verweij, A. Sparreboom, R. Mathôt, 2005, British Journal of Cancer.

The (ir)relevance of plasma protein binding of anticancer drugs.

J. Verweij, A. Sparreboom, W. Loos, 2001, The Netherlands journal of medicine.

Optimal sampling strategies for bayesian estimation of docetaxel (Taxotere) clearance.

J. Verweij, J. Schellens, L. Webster, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Oral Topoisomerase 1 Inhibitors in Adult Patients: Present and Future

J. Verweij, H. Gelderblom, A. Sparreboom, 1999, Investigational New Drugs.

Dose and schedule-finding study of oral topotecan and weekly cisplatin in patients with recurrent ovarian cancer

J. Verweij, H. Gelderblom, A. Sparreboom, 2001, British Journal of Cancer.

Phase I P harmacologic S tudy o f O ral T opotecan a nd Intravenous C isplatin: S equence-Depende nt H ematologic Side E ffects

J. Verweij, H. Gelderblom, A. Sparreboom, 2000 .

Phase I pharmacologic study of oral topotecan and intravenous cisplatin: sequence-dependent hematologic side effects.

J. Verweij, H. Gelderblom, A. Sparreboom, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prevention of Acute Cisplatin-Induced Nausea and Vomiting

J. Verweij, P. Mulder, 1996 .

A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck

M. Piccart, J. Wanders, J. Verweij, 1994 .

Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles

J. Verweij, L. van Zuylen, M. Karlsson, 2001, Cancer Chemotherapy and Pharmacology.

Comparative Pharmacokinetics of Weekly and Every-Three-Weeks Docetaxel

Ming Zhao, Alex Sparreboom, A. Wolff, 2004, Clinical Cancer Research.

Therapeutic Drug Monitoring for the Individualization of Docetaxel Dosing: A Randomized Pharmacokinetic Study

J. Verweij, R. Mathijssen, P. de Bruijn, 2011, Clinical Cancer Research.

Determination of fraction unbound docetaxel using microequilibrium dialysis.

J. Verweij, S. Baker, A. Sparreboom, 2004, Analytical biochemistry.

Sensitive determination of docetaxel in human plasma by liquid-liquid extraction and reversed-phase high-performance liquid chromatography.

J. Verweij, A. Sparreboom, W. Loos, 1997, Journal of chromatography. B, Biomedical sciences and applications.

Radioimmunodetection and Radioimmunotherapy in Myosarcoma

J. Verweij, G. Stoter, A. Planting, 1989 .

Lack of ABC transporter autoinduction in mice following long-term exposure to imatinib

J. Verweij, A. Sparreboom, W. Figg, 2008, Cancer biology & therapy.

Introduction to 'A multitargeted approach: clinical advances in the treatment of solid tumours'.

J. Verweij, D. George, Daniel J George, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Sarcomas.

J. Verweij, 2020, Cancer chemotherapy and biological response modifiers.

Updated results from a phase III trial of sunitinib in GIST patients (pts) for whom imatinib (IM) therapy has failed due to resistance or intolerance.

G. Demetri, J. Verweij, P. Casali, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prospective study on the dose relationship of mitomycin C–induced interstitial pneumonitis

R. Golding, J. Verweij, H. Pinedo, 1987, Cancer.

Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study.

J. Verweij, L. Dirix, D. Wagener, 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

Pazopanib exposure decreases as a result of an ifosfamide-dependent drug–drug interaction: results of a phase I study

S. Sleijfer, J. Verweij, P. de Bruijn, 2013, British Journal of Cancer.

Pazopanib, a new therapy for metastatic soft tissue sarcoma

S. Sleijfer, J. Verweij, 2013, Expert opinion on pharmacotherapy.

Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005.

J. Blay, M. van Glabbeke, J. Verweij, 2007, European journal of cancer.

A phase I study of the combination of daily oral sunitinib with intravenous ifosfamide in patients with advanced solid malignancies

S. Sleijfer, J. Verweij, H. Gelderblom, 2009 .

Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072.

S. Sleijfer, S. Litière, J. Verweij, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

An open-label phase I dose escalation study of KRN951, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 1 in a 4 week on, 2 week off schedule in patients with advanced solid tumors.

J. Verweij, H. Burger, K. Hayashi, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in pleural mesothelioma.

M. J. van den Bent, J. Verweij, J. Schellens, 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line.

J. Verweij, J. Schellens, W. Loos, 1998, British Journal of Cancer.

Liquid chromatographic determination of ketoconazole, a potent inhibitor of CYP3A4-mediated metabolism.

J. Verweij, A. Sparreboom, P. de Bruijn, 2001, Journal of chromatography. B, Biomedical sciences and applications.

Ifosfamide plus doxorubicin in previously untreated patients with advanced soft-tissue sarcoma.

J. Verweij, A. Santoro, H. Mouridsen, 1993, Cancer chemotherapy and pharmacology.

Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.

D. Crowther, J. Verweij, T. Tursz, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients.

J. Verweij, R. de Wit, G. Stoter, 1998, British Journal of Cancer.

Oral piritrexim, an effective treatment for metastatic urothelial cancer.

J. Verweij, S. Kaye, R. de Wit, 1993, British Journal of Cancer.

Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation fo

L. Collette, D. Lacombe, L. Seymour, 2014, European journal of cancer.

Outcome of patients with sarcoma and other mesenchymal tumours participating in phase I trials: a subset analysis of a European Phase I database.

R. Plummer, J. Verweij, J. Schellens, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Factors affecting pharmacokinetic variability of oral topotecan: a population analysis

J. Verweij, A. Sparreboom, W. Loos, 2004, British Journal of Cancer.

Phase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in adults with solid tumors.

R. Salazar, R. Obach, J. Verweij, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group.

J. Wanders, J. Verweij, C. Sessa, 1994, British Journal of Cancer.

Phase I and pharmacologic study of oral ZD9331, a novel nonpolyglutamated thymidylate synthase inhibitor, in adult patients with solid tumors.

J. Verweij, C. Punt, A. Sparreboom, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors.

S. Clarke, J. Verweij, I. Judson, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Early mortality rates: a tool for phase III trials or for changing standard practice?

J. Verweij, J. Smyth, 2004, European Journal of Cancer.

Phase I study of concomitant chemoradiation with raltitrexed in locally advanced head and neck cancer.

P. Jansen, J. Verweij, A. Planting, 2005, European journal of cancer.

Management of intermediate‐prognosis germ‐cell cancer: Results of a phase I/II study of Taxol‐BEP

S. Rodenhuis, J. Verweij, J. Schornagel, 1999, International journal of cancer.

Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcom

S. Sleijfer, J. Blay, S. Rodenhuis, 2010, European journal of cancer.

Piritrexim‐induced Pulmonary Toxicity

J. Verweij, R. de Wit, G. Stoter, 1993, American journal of clinical oncology.

Current sample handling methods for measurement of platinum-DNA adducts in leucocytes in man lead to discrepant results in DNA adduct levels and DNA repair.

J. Verweij, J. Schellens, G. Stoter, 1995, British Journal of Cancer.

Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro

A. W. Boersma, J. Verweij, J. Schellens, 1998, Cancer Chemotherapy and Pharmacology.

Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors.

J. Verweij, J. Schellens, D. V. Von Hoff, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Topotecan in colorectal cancer: a phase II study of the EORTC early clinical trials group.

J. Wanders, J. Verweij, L. Dirix, 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

Nursing care adaptations during clinical trials with weekly high‐dose cisplatin: evaluation of a process plan

J. Verweij, G. Stoter, A. Planting, 1993 .

Disposition of [G-(3)H]paclitaxel and cremophor EL in a patient with severely impaired renal function.

J. Verweij, H. Gelderblom, A. Sparreboom, 1999, Drug metabolism and disposition: the biological fate of chemicals.

The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel.

J. Verweij, L. van Zuylen, A. Sparreboom, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Pharmacokinetic, M etabolic, a nd P harmacodynamic Profiles i n a D ose-Escalating S tudy o f Irinotecan a nd C isplatin

J. Verweij, A. Sparreboom, C. Jacques, 2000 .

Abstracts of papers clinical pharmacological meeting

D. J. Veldhuisen, J. Remon, J. Ottervanger, 2005, Pharmacy World and Science.

Changing concepts in the systemic treatment of locally advanced or metastatic soft tissue sarcomas.

J. Verweij, H. Pinedo, 1993, Cancer treatment and research.

Systemic treatment of advanced or metastatic soft tissue sarcomas.

J. Verweij, H. Pinedo, 1991, Cancer treatment and research.

Soft Tissue Sarcomas: New Developments in the Multidisciplinary Approach to Treatment

J. Verweij, H. Suit, H. Pinedo, 1991, Cancer treatment and research.

Treatment of Soft Tissue Sarcomas

J. Verweij, H. Pinedo, 1989, Cancer treatment and research.

Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer.

J. Verweij, J. Schellens, W. Loos, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. EORTC Soft Tissue and Bone Sarcoma Group.

M. van Glabbeke, J. Verweij, A. V. van Oosterom, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Cyclophosphamide, hexamethylmelamine, adriamycin and cisplatin combination chemotherapy in mixed mesodermal sarcoma of the female genital tract.

J. Verweij, G. Stoter, R. Jansen, 1987, European Journal of Cancer and Clinical Oncology.

Phase I study of a weekly schedule of a fixed dose of cisplatin and escalating doses of paclitaxel in patients with advanced oesophageal cancer.

J. Verweij, M. Polée, A. van der Gaast, 2002, European journal of cancer.

Phase II study of a closely spaced ifosfamide--cisplatin schedule with the addition of G-CSF in advanced non-small-cell lung cancer and malignant melanoma.

J. Verweij, R. de Wit, G. Stoter, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I study of weekly high-dose cisplatin combined with long-term oral etoposide in advanced solid tumors.

J. Verweij, G. Stoter, M. V. D. Van Der Burg, 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

Weekly high-dose cisplatin in malignant pleural mesothelioma.

J. Verweij, J. Schellens, G. Stoter, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Asbestos bodies and fibers in lung tissue

J. Verweij, G. Stoter, M. V. D. Van Der Burg, 1974, Environmental Health Perspectives.

Increasing tumoral 5-fluorouracil concentrations during a 5-day continuous infusion: a microdialysis study

S. Sleijfer, E. Wiemer, J. Verweij, 2010, Cancer Chemotherapy and Pharmacology.

Phase II study of raltitrexed ('Tomudex') for patients with advanced soft tissue sarcomas refractory to doxorubicin-containing regimens.

J. Blay, S. Rodenhuis, M. van Glabbeke, 1999, Anti-cancer drugs.

Antineoplastic Agents

J. Verweij, J. Schellens, E. Meerten, 1995, Drug safety.

Mild to moderate liver dysfunction does not require dose reduction of oral or intravenous vinorelbine: results of a pharmacokinetic study.

J. Verweij, M. D. de Jonge, C. Puozzo, 2010, European Journal of Cancer.

Rational Design of New TumoractivatedTM Cytotoxic Agents

J. Verweij, 1999, Oncology.

Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study.

C. Seynaeve, J. Verweij, P. D. De Mulder, 1990, Annals of internal medicine.

Ondansetron in the prophylaxis of nausea and vomiting induced by cisplatin.

S. Kaasa, C. Seynaeve, J. Verweij, 1990, European Journal of Cancer.

Cancer Drug Development in Europe: A Selection of New Agents Under Development at the European Drug Development Network

D. Lacombe, P. Therasse, J. Verweij, 2003, Cancer Investigation.

Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane

C. Seynaeve, J. Verweij, M. Bontenbal, 2001, Breast Cancer Research and Treatment.

Weekly low-dose mitoxantrone plus doxorubicin as second-line chemotherapy for advanced breast cancer

J. Klijn, J. Verweij, J. Alexieva-Figusch, 1992, Breast Cancer Research and Treatment.

Clinical Management of Soft Tissue Sarcomas

J. Verweij, H. Pinedo, 2011, Cancer Treatment and Research.

A randomized phase I Bayesian dose escalation design for the combination of anti‐cancer drugs

E. Lesaffre, J. Verweij, P. Hamberg, 2014, Pharmaceutical statistics.

Pharmacokinetic results from two phase I dose escalation studies of once daily oral treatment with BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in patients with advanced solid tumors.

J. Verweij, J. Marshall, J. Gietema, 2005 .

RAPID ALKALINISATION FOR FLAVONE ACETIC ACID ADMINISTRATION: A POTENTIALLY HAZARDOUS PROCEDURE

J. Verweij, G. Stoter, P. Dodion, 1988, The Lancet.

Phase I and pharmacokinetic study of halofuginone, an oral quinazolinone derivative in patients with advanced solid tumours.

D. Lacombe, J. Verweij, C. Punt, 2006, European journal of cancer.

Carcinoma of unknown primary: identification of a treatable subset?

J. Verweij, S. Henzen‐Logmans, A. van der Gaast, 1990, Annals of oncology : official journal of the European Society for Medical Oncology.

Abstract LB-201: Updated results from a Phase I study of AV-951 (KRN951), a potent and selective VEGFR-1, -2 and -3 tyrosine kinase inhibitor, in patients with advanced solid tumors

M. Cotreau, J. Verweij, H. Burger, 2008 .

Pathophysiology of cytotoxic drug-induced emesis: far from crystal-clear

C. Seynaeve, J. Verweij, P. Mulder, 1991, Pharmaceutisch Weekblad.

A dose-finding study of miltefosine (hexadecylphosphocholine) in patients with metastatic solid tumours

J. Verweij, G. Stoter, A. Planting, 1992, Journal of Cancer Research and Clinical Oncology.

Increases in leucocyte and platelet counts induced by the alkyl phospholipid hexadecylphosphocholine.

J. Verweij, G. Stoter, L. Pronk, 1994, European journal of cancer.

Phase II study of daily oral miltefosine (hexadecylphosphocholine) in advanced colorectal cancer.

J. Verweij, G. Stoter, A. Planting, 1993, European journal of cancer.

Phase II study of oral miltefosine in patients with squamous cell head and neck cancer.

J. Verweij, J. Armand, G. Stoter, 1993, European journal of cancer.

Phase II study of miltefosine (hexadecylphosphocholine) in advanced soft tissue sarcomas of the adult--an EORTC Soft Tissue and Bone Sarcoma Group Study.

M. van Glabbeke, J. Verweij, M. Glabbeke, 1993, European journal of cancer.

Evaluation of soluble KIT (sKIT) as a potential surrogate marker for TTP in sunitinib malate (SU)-treated patients (pts) with advanced GIST

G. Demetri, J. Verweij, P. Casali, 2007 .

Doxorubicin plus ifosfamide with rhGM-CSF in the treatment of advanced adult soft-tissue sarcomas: preliminary results of a phase II study from the EORTC Soft-Tissue and Bone Sarcoma Group

J. Verweij, M. Glabbeke, W. Steward, 2005, Journal of Cancer Research and Clinical Oncology.

Limited cerebrospinal fluid penetration of docetaxel

J. Verweij, S. Baker, A. Sparreboom, 2004, Anti-cancer drugs.

Population Pharmacokinetic and Dynamic Analysis of the Topoisomerase I Inhibitor Lurtotecan in Phase II Studies

M. Gore, R. Paridaens, J. Wanders, 2002, Investigational New Drugs.

5-Fluorouracil, doxorubicin and mitomycin C (FAM) combination chemotherapy for metastatic adenocarcinoma of unknown primary.

J. Verweij, A. van der Gaast, G. Stoter, 1988, European Journal of Cancer and Clinical Oncology.

The use of a systemic therapy checklist improves the quality of data acquisition and recording in multicentre trials. A study of the EORTC Soft Tissue and Bone Sarcoma Group.

O. S. Nielsen, P. Therasse, J. Verweij, 1997, European journal of cancer.

Pharmacokinetics of ifosfamide are changed by combination with docetaxel: results of a phase I pharmacologic study.

M. Highley, J. Verweij, A. V. van Oosterom, 2000, American journal of clinical oncology.

Advances in Cancer Therapeutics

J. Verweij, A. Sparreboom, Alex Sparreboom, 2009, Clinical pharmacology and therapeutics.

Phase II study on cisplatin and ifosfamide in recurrent high grade gliomas.

M. J. van den Bent, J. Verweij, J. Schellens, 1998, European Journal of Cancer.

The applicability of mTOR inhibition in solid tumors.

S. Sleijfer, E. Wiemer, J. Verweij, 2009, Current cancer drug targets.

Quantification of [3H]docetaxel in feces and urine: development and validation of a combustion method

J. Verweij, E. Krenning, W. Loos, 2006, Anti-Cancer Drugs.

Docetaxel in 253 previously treated patients with progressive locally advanced or metastatic breast cancer: results of a compassionate use program in The Netherlands

J. Verweij, J. Beijnen, W. W. ten Bokkel Huinink, 2000, Anti-Cancer Drugs.

Progression of paclitaxel‐induced neuropathy following discontinuation of treatment

M. J. van den Bent, J. Verweij, P. S. Sillevis Smitt, 1997, Muscle and Nerve.

Adjuvant therapy in primary GIST: state-of-the-art.

J. Blay, J. Verweij, H. Joensuu, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Paclitaxel (Taxol) induces cumulative mild neurotoxicity.

M. J. van den Bent, J. V. van Gerven, J. Verweij, 1994, European journal of cancer.

Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis

S. Sleijfer, J. Verweij, A. Eggermont, 2008, Anti-cancer drugs.

Capecitabine in breast cancer: current status.

J. Verweij, M. Bontenbal, C. Smorenburg, 2001, Clinical breast cancer.

Phase I and pharmacokinetic study of Xeloda TM (capecitabine) in combination with docetaxel

J. Verweij, P. Vasey, A. Sparreboom, 1997 .

Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.

L B Sheiner, A Riva, P M Ravdin, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Influence of ketoconazole on the fecal and urinary disposition of docetaxel

J. Verweij, W. Loos, R. V. Schaik, 2007, Cancer Chemotherapy and Pharmacology.

Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC Early Clinical Trials Group.

S. Aamdal, R. Paridaens, J. Wanders, 1994, European journal of cancer.

Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group.

L. Gras, J. Wanders, J. Verweij, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Preclinical evaluation of alternative pharmaceutical delivery vehicles for paclitaxel

J. Verweij, A. Sparreboom, W. Loos, 2002, Anti-cancer drugs.

Efficacy and side effects of two chemotherapy regimens with cisplatin plus fluorouracil in advanced squamous cell carcinoma of the head and neck.

J. Verweij, P. Schmitz, G. Stoter, 1990, Annals of oncology : official journal of the European Society for Medical Oncology.

Interactionof Cisplatinwith the HumanOrganic CationTransporter 2

J. Verweij, A. Sparreboom, W. Loos, 2008 .

Population pharmacokinetics of cisplatin in adult cancer patients

J. Verweij, A. Sparreboom, J. Gallo, 2004, Cancer Chemotherapy and Pharmacology.

Modulation of cisplatin pharmacodynamics by Cremophor EL: experimental and clinical studies.

J. Verweij, H. Gelderblom, A. Sparreboom, 2002, European Journal of Cancer.

Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients.

J. Verweij, J. von Pawel, U. Gatzemeier, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Determination of irinotecan (CPT-11) and its active metabolite SN-38 in human plasma by reversed-phase high-performance liquid chromatography with fluorescence detection.

J. Verweij, A. Sparreboom, P. de Bruijn, 1997, Journal of chromatography. B, Biomedical sciences and applications.

Randomised phase II trial of carboplatin and iproplatin in advanced urothelial cancer.

C. Seynaeve, J. Verweij, R. de Wit, 1991, European journal of cancer.

The pharmacokinetic plasma profile of mitomycin C, measured after sequential intermittent intravenous administration.

J. Lankelma, J. Verweij, H. Pinedo, 1988, European Journal of Cancer and Clinical Oncology.

A phase I dose escalating study of the angiogenesis inhibitor thrombospondin-1 mimetic (ABT-510) in patients with advanced cancer

J. Verweij, R. Hoekstra, R. Humerickhouse, 2002 .

Primary care in cancer control: towards mature cancer care.

J. De Maeseneer, J. Verweij, W. Brouwer, 2015, The Lancet Oncology.

Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in metastatic colorectal cancer.

M. J. van den Bent, J. Verweij, G. Stoter, 1996, British Journal of Cancer.

Phase I and pharmacologic study of oral (PEG-1000) 9-aminocamptothecin in adult patients with solid tumors.

J. Verweij, C. Punt, A. Sparreboom, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedure

S. Rodenhuis, J. Verweij, J. Schellens, 1996, Cancer Chemotherapy and Pharmacology.

Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans.

J. Verweij, L. van Zuylen, A. Sparreboom, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Determination of topotecan in human whole blood and unwashed erythrocytes by high-performance liquid chromatography.

J. Verweij, H. Gelderblom, A. Sparreboom, 2002, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Cyclophosphamide versus ifosfamide: a randomized phase II trial in adult soft-tissue sarcomas. The European Organization for Research and Treatment of Cancer [EORTC], Soft Tissue and Bone Sarcoma Group.

J. Verweij, R. Sylvester, A. Santoro, 1993, Cancer chemotherapy and pharmacology.

EORTC joint ventures in quality control: treatment-related variables and data acquisition in chemotherapy trials.

J. Verweij, A. V. van Oosterom, W. Steward, 1991, European journal of cancer.

A phase I, open-label study of the safety and pharmacokinetics (PK) of pazopanib (P) and lapatinib (L) administered concurrently.

J. Verweij, H. Hurwitz, A. Suttle, 2006, Journal of Clinical Oncology.

Aurora kinase inhibitors.

J. Verweij, M. D. de Jonge, M. D. de Jonge, 2010, Critical reviews in oncology/hematology.

Drug transporters of platinum-based anticancer agents and their clinical significance.

E. Wiemer, J. Verweij, R. Mathijssen, 2011, Drug resistance updates.

Modulation of irinotecan metabolism by ketoconazole.

Ron H J Mathijssen, Alex Sparreboom, J. Verweij, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group.

A. te Velde, J. Verweij, L. Dirix, 1996, European journal of cancer.

Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug E09.

J. Verweij, J. Schellens, W. Loos, 1994, Journal of the National Cancer Institute.

Complementary and alternative medicine during cancer treatment: beyond innocence.

J. Verweij, R. Mathijssen, F. D. de Jong, 2006, The oncologist.

How to Define Treatment Success or Failure if Tumors Do Not Shrink

J. Verweij, M. D. Jonge, J. Kitzen, 2008 .

Using single-agent therapy in adult patients with advanced soft tissue sarcoma can still be considered standard care.

S. Sleijfer, C. Seynaeve, J. Verweij, 2005, The oncologist.

Targeted therapy: ready for prime time?

C. Seynaeve, J. Verweij, 2004, Cancer treatment and research.

Phase II study of miltefosine 6% solution as topical treatment of skin metastases in breast cancer patients

C. Seynaeve, H. Sindermann, J. Verweij, 2000, Anti-cancer drugs.

Lessons learned from independent central review.

L. Schwartz, D. Sargent, L. Dodd, 2009, European journal of cancer.

A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group.

M. Piccart, J. Wanders, J. Verweij, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[Severe tissue necrosis due to extravasation of mitomycin].

J. Verweij, A. V. van Geel, G. Stoter, 1987, Nederlands tijdschrift voor geneeskunde.

Severe side effects of the cytotoxic drug mitomycin-C.

J. Verweij, G. Stoter, 1987, The Netherlands journal of medicine.

Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.

J. Verweij, A. Santoro, H. Mouridsen, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Surrogate endpoints in advanced sarcoma trials: a meta-analysis

J. Blay, S. Litière, J. Verweij, 2018, OncoTarget.

Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043).

Patrick Schöffski, Jean-Yves Blay, Françoise Collin, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group.

J. Blay, M. van Glabbeke, J. Verweij, 2008, European journal of cancer.

Paclitaxel in patients (pts) with advanced angiosarcomas

J. Blay, J. Verweij, M. Schlemmer, 2007 .

Determination of camptothecin analogs in biological matrices by high-performance liquid chromatography

J. Verweij, A. Sparreboom, P. de Bruijn, 2000, Anti-cancer drugs.

Liposomal lurtotecan (NX211): determination of total drug levels in human plasma and urine by reversed-phase high-performance liquid chromatography.

J. Verweij, A. Sparreboom, P. de Bruijn, 2000, Journal of chromatography. B, Biomedical sciences and applications.

Femtomole quantitation of 7-ethyl-10-hydroxycamptothecine (SN-38) in plasma samples by reversed-phase high-performance liquid chromatography.

J. Verweij, A. Sparreboom, P. de Bruijn, 1999, Analytical biochemistry.

蛍光検出逆相高速液体クロマトグラフィーによるヒト血しょう中イリノテカン(CPT‐11)とその活性代謝産物SN‐38の定量

J. Verweij, A. Sparreboom, G. Stoter, 1997 .

Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.

J. Blay, M. van Glabbeke, J. Verweij, 2007, European journal of cancer.

Hepatic transport, Metabolism and biliary excretion of irinotecan in a cancer patient with an external bile drain

J. Verweij, P. de Bruijn, W. Loos, 2006, Cancer biology & therapy.

Development of Multidrug-Resistance Convertors: Sense or Nonsense?

J. Verweij, L. van Zuylen, A. Sparreboom, 2000, Investigational New Drugs.

The use of protons in cancer therapy at PSI and related instrumentation

J. M. Schippers, H. W. Reist, Eros Pedroni, 2006 .

Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of

J. Blay, S. Rodenhuis, M. van Glabbeke, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours

J. Blay, M. van Glabbeke, R. Sciot, 2010, Histopathology.

Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy

J. Verweij, A. Sparreboom, R. de Wit, 2001, British Journal of Cancer.

Initial high anti-emetic efficacy of granisetron with dexamethasone is not maintained over repeated cycles.

J. Verweij, R. de Wit, M. Fonteyn, 1998, British Journal of Cancer.

Circulating Levels of Soluble KIT Serve as a Biomarker for Clinical Outcome in Gastrointestinal Stromal Tumor Patients Receiving Sunitinib following Imatinib Failure

Xin Huang, Patrick Schöffski, G. Demetri, 2009, Clinical Cancer Research.

Multicentre phase II pharmacological evaluation of rhizoxin. Eortc early clinical studies (ECSG)/pharmacology and molecular mechanisms (PAMM) groups.

S. Aamdal, H. McLeod, J. Wanders, 1996, British Journal of Cancer.

Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors

J. Verweij, P. Workman, I. Judson, 2009, Molecular Cancer Therapeutics.

Clinical studies of camptothecin and derivatives.

J. Verweij, A. Sparreboom, O. Soepenberg, 2003, The Alkaloids. Chemistry and biology.

Phase II clinical trials with rhizoxin in breast cancer and melanoma. The EORTC Early Clinical Trials Group.

A. te Velde, S. Aamdal, R. Paridaens, 1996, British Journal of Cancer.

Phase II study of recombinant interferon alpha-2a and vinblastine in advanced renal cell carcinoma.

J. Klijn, J. Verweij, J. Schornagel, 1989, Journal of Urology.

Alternative drug formulations of docetaxel: a review.

J. Verweij, R. Mathôt, F. Engels, 2007, Anti-cancer drugs.

Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group.

M. van Glabbeke, A. Hagemeijer, R. Sciot, 2004, European journal of cancer.

Clinical Pharmacokinetics of 2′-Deoxy-2′-Methylidenecytidine (DMDC), a Deoxycytidine Analogue Antineoplastic Agent

J. Verweij, R. Gordon, A. Gaast, 2000, Clinical pharmacokinetics.

A Phase I Study of a New Nucleoside Analogue, OSI-7836, Using Two Administration Schedules in Patients with Advanced Solid Malignancies

J. Verweij, I. Judson, S. Kaye, 2006, Clinical Cancer Research.

Phase II study on mitoxantrone in adenoid cystic carcinomas of the head and neck

A. Graeff, J. Verweij, J. Schornagel, 1996 .

Epirubicin in patients with advanced or recurrent adenoid cystic carcinoma of the head and neck: a phase II study of the EORTC Head and Neck Cancer Cooperative Group.

S. Rodenhuis, G. Snow, J. Verweij, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.

Jordi Rodon, Diana Birle, J. Baselga, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Soft tissue sarcomas of adults: state of the translational science.

P. Meltzer, M. Ladanyi, J. Fletcher, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study

Sigrid Stroobants, Sasa Dimitrijevic, Ian Judson, 2001, The Lancet.

A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas.

J. Blay, G. Demetri, J. Verweij, 2012, European journal of cancer.

Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.

J. Blay, C. Fisher, S. Litière, 2014, The Lancet. Oncology.

Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.

J. Blay, S. Rodenhuis, M. van Glabbeke, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients.

O. S. Nielsen, M. van Glabbeke, J. Verweij, 2002, European journal of cancer.

Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas.

O. S. Nielsen, M. van Glabbeke, J. Verweij, 2002, European journal of cancer.

Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group.

J. Blay, J. Radford, J. Verweij, 2001, European journal of cancer.

High-dose DTIC in advanced soft-tissue sarcomas in the adult. A phase II study of the E.O.R.T.C. Soft Tissue and Bone Sarcoma Group.

J. Verweij, R. Sylvester, H. Mouridsen, 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

Influence of Genetic Variants in UGT1A1 and UGT1A9 on the In Vivo Glucuronidation of SN‐38

J. Verweij, A. Sparreboom, R. Danesi, 2004, Journal of clinical pharmacology.

Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38

J. Verweij, A. Sparreboom, R. Danesi, 2004 .

Outcome of Patients with Platelet-Derived Growth Factor Receptor Alpha–Mutated Gastrointestinal Stromal Tumors in the Tyrosine Kinase Inhibitor Era

J. Blay, M. van Glabbeke, F. Bertucci, 2012, Clinical Cancer Research.

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

Xin Huang, J. Desai, G. Demetri, 2006, The Lancet.

Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.

M. van Glabbeke, D. Crowther, J. Verweij, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial.

O. S. Nielsen, J. Blay, S. Rodenhuis, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Long-term Prospective Population Pharmacokinetic Study on Imatinib Plasma Concentrations in GIST Patients

E. Wiemer, M. Fransson, J. Verweij, 2012, Clinical Cancer Research.

Targeting Treatment of Soft Tissue Sarcomas

J. Verweij, H. Pinedo, 2013, Cancer Treatment and Research.

Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas.

J. Blay, M. van Glabbeke, J. Verweij, 2009, Cancer research.

Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin.

M. J. van den Bent, J. Verweij, W. van Putten, 1997, British Journal of Cancer.

Simple prognostic model to predict survival in patients with undifferentiated carcinoma of unknown primary site.

W. Hop, J. Verweij, A. van der Gaast, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Role of Formulation Vehicles in Taxane Pharmacology

Alex Sparreboom, J. Verweij, L. van Zuylen, 2001, Investigational New Drugs.

Precision oncology: an overview.

Levi A Garraway, L. Garraway, J. Verweij, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MicroRNA expression profiles distinguish liposarcoma subtypes and implicate miR‐145 and miR‐451 as tumor suppressors

Stefan Sleijfer, Cornelis Verhoef, S. Sleijfer, 2014, International journal of cancer.

Phase II study on mitoxantrone in adenoid cystic carcinomas of the head and neck. EORTC Head and Neck Cancer Cooperative Group.

J. Verweij, J. Schornagel, F. Cognetti, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Mitomycin C-induced organ toxicity in Wistar rats: a study with special focus on the kidney

J. Verweij, H. Pinedo, S. Kerpel-Fronius, 2004, Journal of Cancer Research and Clinical Oncology.

Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in metastatic malignant melanoma.

J. Verweij, J. Schellens, C. Vecht, 1996, European journal of cancer.

Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group.

Sigrid Stroobants, O. S. Nielsen, Sasa Dimitrijevic, 2002, European journal of cancer.

Adaptive intrapatient dose escalation of cisplatin in patients with advanced head and neck cancer

J. Verweij, J. Schellens, A. D. de Vos, 2001, Anti-cancer drugs.

Short report: Phase II study of cisplatin plus 24-hour infusion of ifosfamide in advanced malignant melanoma

J. Verweij, G. Stoter, A. Planting, 1990 .

Phase II study of cisplatin plus 24-hour infusion of ifosfamide in advanced malignant melanoma.

J. Verweij, A. van der Gaast, G. Stoter, 1990, Annals of oncology : official journal of the European Society for Medical Oncology.

The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review.

J. Verweij, Jaap Verweij, F. Eskens, 2006, European journal of cancer.

Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours.

J. Verweij, J. Schellens, P. Schmitz, 1996, British Journal of Cancer.

miR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathway

E. Berns, Marijn T. M. van Jaarsveld, A. W. Boersma, 2015, Molecular Cancer.

miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells

E. Berns, A. W. Boersma, E. Wiemer, 2013, Oncogene.

Indium111 antimyosin for the detection of leiomyosarcoma and rhabdomyosarcoma

P. H. Cox, J. Verweij, G. Stoter, 2004, European Journal of Nuclear Medicine.

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

Rossella Bertulli, Jean-Yves Blay, Ian Judson, 2004, The Lancet.

Phase II study of liposomal muramyl tripeptide phosphatidylethanolamine (MTP/PE) in advanced soft tissue sarcomas of the adult. An EORTC Soft Tissue and Bone Sarcoma Group study.

M. van Glabbeke, J. Verweij, H. Mouridsen, 1994, European journal of cancer.

MiR-17-92 and miR-221/222 cluster members target KIT and ETV1 in human gastrointestinal stromal tumours

S. Sleijfer, A. W. Boersma, E. Wiemer, 2013, British Journal of Cancer.

Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients

M. J. van den Bent, J. Verweij, W. Graveland, 2003, British Journal of Cancer.

Pharmacogenetics of ABCG2 and adverse reactions to gefitinib.

M. Hidalgo, J. Verweij, R. Ingersoll, 2006, Journal of the National Cancer Institute.

Future treatment of soft tissue sarcomas will be driven by histological subtype and molecular aberrations.

J. Verweij, L. Baker, 2010, European journal of cancer.

Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan.

J. Verweij, A. Sparreboom, R. Mathijssen, 2002, Current cancer drug targets.

Non-islet-cell tumor induced hypoglycemia in patients with advanced gastrointestinal stromal tumor possibly worsened by imatinib.

S. Sleijfer, J. Verweij, P. Hamberg, 2006, Journal of Clinical Oncology.

Determining the optimal dose in the development of anticancer agents

J. Verweij, A. Sparreboom, R. Mathijssen, 2014, Nature Reviews Clinical Oncology.

Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps

Mariël Brok, E. Wiemer, J. Verweij, 2005, Cancer biology & therapy.

Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype

Sharon Marsh, Howard L McLeod, Alex Sparreboom, 2004, Clinical pharmacology and therapeutics.

Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein.

J Verweij, J. Verweij, A. Sparreboom, 1999, Anti-cancer drugs.

Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2.

J. Verweij, A. Sparreboom, W. Figg, 2005, Pharmacogenomics.

Activity and toxicity of GI147211 in breast, colorectal and non-small-cell lung cancer patients: an EORTC-ECSG phase II clinical study.

R. Paridaens, J. Wanders, J. Verweij, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x 5 intravenous administration.

J. Verweij, J. Schellens, A. Planting, 1996, British Journal of Cancer.

Effects of St. John's wort on irinotecan metabolism.

J. Verweij, A. Sparreboom, R. Mathijssen, 2002, Journal of the National Cancer Institute.

Effect of Common CYP3A4 and CYP3A5 Variants on the Pharmacokinetics of the Cytochrome P450 3A Phenotyping Probe Midazolam in Cancer Patients

S. Bates, J. Verweij, R. Ingersoll, 2005, Clinical Cancer Research.

Effect of Common CYP 3 A 4 and CYP 3 A 5 Variants on the Pharmacokinetics of the Cytochrome P 450 3 A Phenotyping ProbeMidazolam in Cancer Patients

S. Bates, J. Verweij, R. Ingersoll, 2005 .

The epothilone dilemma.

J. Verweij, M. D. de Jonge, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study of epidoxorubicin in colorectal cancer and the use of cyclosporin-A in an attempt to reverse multidrug resistance.

C. Seynaeve, J. Verweij, H. Herweijer, 1991, British Journal of Cancer.

Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications.

J Verweij, J. Verweij, L. van Zuylen, 1999, Cancer research.

Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 Polymorphisms with the Pharmacokinetics of Paclitaxel

Sharon Marsh, Mats O Karlsson, Howard L McLeod, 2005, Clinical Cancer Research.

A Phase I and Pharmacokinetic Study of Weekly Paclitaxel and Carboplatin in Patients with Metastatic Esophageal Cancer

J. Verweij, A. Sparreboom, R. Hoekstra, 2004, Clinical Cancer Research.

Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes.

J. Verweij, W. Graveland, A. Sparreboom, 2004, Journal of the National Cancer Institute.

Topotecan lacks third space sequestration.

J. Verweij, H. Gelderblom, A. Sparreboom, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients.

B. Reigner, J. Verweij, B. Osterwalder, 1998, Clinical Cancer Research.

Effect of Cytochrome P450 3A4 Inhibition on the Pharmacokinetics of Docetaxel

J. Verweij, S. Baker, A. Sparreboom, 2004, Clinical pharmacology and therapeutics.

Population Pharmacokinetic Model for Docetaxel in Patients with Varying Degrees of Liver Function: Incorporating Cytochrome P450 3A Activity Measurements

J. Verweij, H. Gelderblom, E. Garrett-Mayer, 2008, Clinical pharmacology and therapeutics.

Relationship of Systemic Exposure to Unbound Docetaxel and Neutropenia

J. Verweij, W. Graveland, S. Baker, 2005, Clinical pharmacology and therapeutics.

The influence of functional polymorphisms in UGT1A7 and UGT1A9 on irinotecan pharmacokinetics in Asian cancer patients

J. Verweij, E. Tan, A. Sparreboom, 2005 .

Molecular mechanisms of interethnic differences in irinotecan disposition: Impact of variants in ABCG2

J. Verweij, E. Tan, S. Baker, 2005 .

Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor

J. Verweij, Sunil Sharma, M. D. de Jonge, 2011, Cancer Chemotherapy and Pharmacology.

Paclitaxel repackaged in an albumin-stabilized nanoparticle: handy or just a dandy?

J. Verweij, S. Baker, A. Sparreboom, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of ABCG2 genotype and mRNA expression on the bioavailability of topotecan.

J. Verweij, H. Gelderblom, A. Sparreboom, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dosing strategies for anticancer drugs: the good, the bad and body-surface area.

J Verweij, J. Verweij, A. Sparreboom, 2002, European journal of cancer.

Phase II trial of methylene dimethane sulphonate (MDMS) in advanced soft tissue sarcomas of the adult. A study of the EORTC Soft Tissue and Bone Sarcoma Group.

J. Verweij, R. Sylvester, H. Mouridsen, 1989, European journal of cancer & clinical oncology.

Factors Affecting Cytochrome P-450 3A Activity in Cancer Patients

J. Verweij, S. Clarke, M. Carducci, 2004, Clinical Cancer Research.

Medicinal cannabis does not influence the clinical pharmacokinetics of irinotecan and docetaxel.

J. Verweij, A. Sparreboom, R. Mathijssen, 2007, The oncologist.

A CYP3A4 Phenotype–Based Dosing Algorithm for Individualized Treatment of Irinotecan

E. Wiemer, J. Verweij, A. Sparreboom, 2010, Clinical Cancer Research.

Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia.

J. Verweij, A. Sparreboom, R. Mathijssen, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I and pharmacologic study of the matrix metalloproteinase inhibitor CP-471,358 in patients with advanced solid tumors

J. Verweij, D. Noe, P. Schöffski, 2005, Cancer Chemotherapy and Pharmacology.

Matrix metalloproteinase inhibitors: current developments and future perspectives.

J. Verweij, F. Eskens, R. Hoekstra, 2001, The Oncologist.

Combination therapy of ACNU and ifosfamide in tumor bearing mice with M2661 breast cancer, B16 malignant melanoma or C38 colon cancer.

J. Verweij, G. Stoter, K. Nooter, 1990, European journal of cancer.

Phase I and Pharmacologic Study of PKI166, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients with Advanced Solid Malignancies

C. Bucana, J. Verweij, I. Fidler, 2005, Clinical Cancer Research.

Treatment of patients with metastatic pancreatic and gastrointestinal tumours with the somatostatin analogue Sandostatin: a phase II study including endocrine effects.

J. Foekens, J. Klijn, J. Verweij, 1990, British Journal of Cancer.

Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors

J. Verweij, H. Hurwitz, P. Hamberg, 2013, Investigational new drugs.

Phase II Study of Weekly Dose-intensified Cisplatin Chemotherapy with Oral Etoposide in Recurrent Glioma

M. J. van den Bent, J. Verweij, C. Vecht, 1999, Journal of Neuro-Oncology.

Modifying phase I methodology to facilitate enrolment of molecularly selected patients.

K. Flaherty, G. Demetri, J. Verweij, 2013, European Journal of Cancer.

Moving molecular targeted drug therapy towards personalized medicine: Issues related to clinical trial design

S. Sleijfer, J. Verweij, M. D. de Jonge, 2012, Molecular oncology.

Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials.

S. Sleijfer, S. Litière, J. Verweij, 2015, European journal of cancer.

Complete Longitudinal Analyses of the Randomized, Placebo-Controlled, Phase III Trial of Sunitinib in Patients with Gastrointestinal Stromal Tumor following Imatinib Failure

David Goldstein, Serge Leyvraz, Patrick Schöffski, 2012, Clinical Cancer Research.

Drug Insight: gastrointestinal stromal tumors (GIST)—the solid tumor model for cancer-specific treatment

S. Sleijfer, E. Wiemer, J. Verweij, 2008, Nature Clinical Practice Oncology.

GIST as the model of paradigm shift towards targeted therapy of solid tumors: update and perspective on trial design.

S. Sleijfer, C. Seynaeve, J. Verweij, 2008, Advances in experimental medicine and biology.

Improved insight into resistance mechanisms to imatinib in gastrointestinal stromal tumors: a basis for novel approaches and individualization of treatment.

S. Sleijfer, E. Wiemer, C. Seynaeve, 2007, The oncologist.

Practical aspects of managing gastrointestinal stromal tumors.

S. Sleijfer, E. Wiemer, C. Seynaeve, 2006, Clinical colorectal cancer.

Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg.

J. Blay, M. van Glabbeke, J. Verweij, 2005, European journal of cancer.

Docetaxel (Taxotere): a new anti-cancer drug with promising potential?

J. Verweij, 1994, British Journal of Cancer.

Single agent activity of rhizoxin in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group.

A. te Velde, J. Wanders, J. Verweij, 1996, British Journal of Cancer.

Influence of the cisplatin hydration schedule on topotecan pharmacokinetics.

J. Verweij, H. Gelderblom, A. Sparreboom, 2003, European journal of cancer.

Interaction of Cisplatin with the Human Organic Cation Transporter 2

J. Verweij, A. Sparreboom, W. Loos, 2008, Clinical Cancer Research.

EDATREXATE VERSUS METHOTREXATE IN HEAD AND NECK SCC 1651

A. Graeff, J. Verweij, J. Armand, 2019 .

The value of immunohistochemistry in patients with poorly differentiated adenocarcinomas and undifferentiated carcinomas of unknown primary

J. Verweij, S. Henzen‐Logmans, G. Stoter, 1996, Journal of Cancer Research and Clinical Oncology.

Randomized phase III trial of edatrexate versus methotrexate in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck: a European Organization for Research and Treatment of Cancer Head and Neck Cancer Cooperative Group study.

A. Graeff, J. Verweij, J. Schornagel, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of patient enrollment in oncology phase I clinical trials.

E. Wiemer, J. Verweij, B. van der Holt, 2013, The Oncologist.

Individual patient data analysis to assess modifications to the RECIST criteria.

Robert Ford, Larry Rubinstein, Elizabeth Eisenhauer, 2009, European journal of cancer.

A Phase I Pharmacokinetic and Pharmacodynamic Study of the Farnesyl Transferase Inhibitor BMS-214662 in Combination with Cisplatin in Patients with Advanced Solid Tumors

H. Mackay, J. Verweij, R. Hoekstra, 2004, Clinical Cancer Research.

Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib.

J. Verweij, M. D. de Jonge, A. Mita, 2010, European journal of cancer.

Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial.

J. Verweij, S. Bonvalot, F. van Coevorden, 2012, The Lancet. Oncology.

Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists.

J. Verweij, P. Schmitz, R. de Wit, 1997, British Journal of Cancer.

Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients

J. Verweij, W. Loos, R. Wit, 2007, Cancer Chemotherapy and Pharmacology.

Analysis of cumulative probabilities shows that the efficacy of 5HT3 antagonist prophylaxis is not maintained.

J. Verweij, P. D. De Mulder, P. Schmitz, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The 5-HT3 receptor antagonist ondansetron re-establishes control in refractory emesis induced by non-cisplatin chemotherapy.

C. Seynaeve, J. Verweij, P. D. De Mulder, 1991, Clinical oncology (Royal College of Radiologists (Great Britain)).

Phase I and pharmacokinetic study of XR11576, an oral topoisomerase I and II inhibitor, administered on days 1–5 of a 3-weekly cycle in patients with advanced solid tumours

J. Verweij, I. Judson, S. Kaye, 2004, British Journal of Cancer.

Phase II study with Docetaxel (Taxotere®) in advanced soft tissue sarcomas of the adult

J. Verweij, M. Glabbeke, H. Mouridsen, 1994 .

Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma: The EORTC 62961-ESHO 95 Randomized Clinical Trial

Peter Wust, Ulrich Mansmann, Claus Belka, 2018, JAMA oncology.

Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study.

H. Burger, J. Verweij, E. Van Cutsem, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer.

B. Reigner, J. Verweij, J. Schellens, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study on docetaxel and ifosfamide in patients with advanced solid tumours.

J. Verweij, A. V. van Oosterom, J. Schellens, 1998, British Journal of Cancer.

Active transepithelial transport of irinotecan (CPT-11) and its metabolites by human intestinal Caco-2 cells

J. Verweij, H. Takano, A. Sparreboom, 2001, Anti-cancer drugs.

SDHA mutations in adult and pediatric wild-type gastrointestinal stromal tumors

M. O'sullivan, J. Verweij, W. Dinjens, 2013, Modern Pathology.

Adjuvant therapy in primary GIST: state-of-the-art.

J. Blay, J. Verweij, A. Cesne, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Gastrointestinal Stromal Tumors

S. Sleijfer, J. Verweij, 2006 .

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

J. Desai, G. Demetri, J. Verweij, 2006, The Lancet.

Imatinib and gastrointestinal stromal tumors: Where do we go from here?

J. Verweij, U. de Giorgi, 2005, Molecular Cancer Therapeutics.

KIT and PDGF as targets.

J. Verweij, 2004, Cancer treatment and research.

Role of imatinib mesylate (Gleevec®/Glivec®) in gastrointestinal stromal tumors

J. Verweij, F. D. de Jong, 2003, Expert review of anticancer therapy.

Trabectedin (Tr) in the treatment of advanced uterine leiomyosarcomas (U-LMS): Results of a pooled analysis of five single-agent phase II studies using the recommended dose.

J. Blay, G. Demetri, J. Radford, 2010 .

A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma.

J W Oosterhuis, J Verweij, M. van Glabbeke, 2001, European journal of cancer.

Cell Cycle/Apoptosis Molecule Expression Correlates with Imatinib Response in Patients with Advanced Gastrointestinal Stromal Tumors

J. Blay, M. van Glabbeke, R. Sciot, 2009, Clinical Cancer Research.

Inter- and intrapatient variability in oral topotecan pharmacokinetics: implications for body-surface area dosage regimens.

J. Verweij, H. Gelderblom, A. Sparreboom, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Chemotherapy treatment patterns and clinical outcomes in patients with metastatic soft tissue sarcoma. The SArcoma treatment and Burden of Illness in North America and Europe (SABINE) study.

J. Blay, J. Verweij, I. Judson, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy.

O. S. Nielsen, J. Blay, M. van Glabbeke, 2003, European journal of cancer.

Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group.

O. S. Nielsen, J. Blay, M. van Glabbeke, 2000, European journal of cancer.

Cytotoxic therapy for the elderly with metastatic breast cancer: a review on safety, pharmacokinetics and efficacy.

C. Seynaeve, J. Verweij, P. Hamberg, 2007, European journal of cancer.

Epirubicin is not Superior to Doxorubicin in the Treatment of Advanced Soft Tissue Sarcomas.The Experience of the EORTC Soft Tissue and Bone Sarcoma Group

O. S. Nielsen, M. van Glabbeke, J. Verweij, 2000, Sarcoma.

High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group.

O. S. Nielsen, M. van Glabbeke, D. Crowther, 1998, British Journal of Cancer.

Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up.

S. Sleijfer, J. Verweij, P. Casali, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Neoadjuvant Chemotherapy Plus Regional Hyperthermia and Long-termOutcomes Among PatientsWith Localized High-Risk Soft Tissue Sarcoma The EORTC 62961-ESHO 95 Randomized Clinical Trial

W. Hiddemann, P. Wust, U. Mansmann, 2017 .

Soft tissue sarcoma trials: one size no longer fits all.

J. Verweij, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tumor Volume as an Alternative Response Measurement for Imatinib Treated GIST Patients

Dave J. Bekers, Gabriel P. Krestin, Patrick Schöffski, 2012, PloS one.

The EORTC and drug development

D. Lacombe, G. Jayson, J. Verweij, 2002 .

Second-line chemotherapy with long-term low-dose oral etoposide in patients with advanced breast cancer

J. Klijn, J. Verweij, M. Bontenbal, 1995, Breast Cancer Research and Treatment.

Recurrence of melanoma following T cell treatment: continued antigen expression in a tumor that evades T cell recruitment.

N. Taylor, J. Verweij, A. Sewell, 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials.

J. Blay, S. Litière, J. Verweij, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I dose-escalation study of F60008, a novel apoptosis inducer, in patients with advanced solid tumours.

J. Verweij, C. Lamers, M. D. de Jonge, 2009, European Journal of Cancer.

Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase 1 study in patients with advanced solid malignancies

S. Sleijfer, J. Verweij, W. Loos, 2006 .

Lhermitte's sign following chemotherapy with docetaxel

M. J. van den Bent, J. Verweij, M. Bontenbal, 1998, Neurology.

Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors.

Riccardo Spinelli, J. Verweij, J. Nortier, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy.

I Judson, J Verweij, J. Blay, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Multiple targeted tyrosine kinase inhibition in the clinic: all for one or one for all?

J. Verweij, M. D. de Jonge, 2006, European journal of cancer.

'No risk, no fun': challenges for the oncology phase I clinical trial time-performance.

J. Verweij, 2008, European journal of cancer.

Should high-dose chemotherapy be used in the treatment of soft tissue sarcoma?

D. Crowther, J. Verweij, P. Reichardt, 1997, European journal of cancer.

1LBA Impact of regional hyperthermia (RHT) on response to neo-adjuvant chemotherapy and survival of patients with high-risk soft-tissue sarcoma (HR-STS): Results of the randomized EORTC-ESHO intergroup trial (NCI-00003052)

J. Blay, W. Hiddemann, U. Mansmann, 2009 .

Pharmacokinetics of the multidrug-resistance-converting drug dexniguldipine and its pyridine metabolite M-1 in the plasma, tumor, and renal tissue of tumor-bearing Wag / Rij rats

J. Verweij, A. Eggermont, J. Schellens, 1997, Cancer Chemotherapy and Pharmacology.

A phase II trial of 10-Ethyl-10-deaza-aminopterin, a novel antifolate, in patients with advanced and/or recurrent squamous cell carcinoma of the head and neck

J. Verweij, J. Schornagel, J. Armand, 1992 .

Complete Remission of a Brain Metastasis to Third‐Line Hormonal Treatment with Megestrol Acetate

J. Verweij, J. Alexieva-Figusch, A. van der Gaast, 1990, American journal of clinical oncology.

Dispelling the myths around cancer care delivery: It's not all about costs

J. Verweij, R. Sullivan, E. Vries, 2014 .

Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study.

M. van Glabbeke, R. Sciot, J. Verweij, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

RECIST vs. WHO: prospective comparison of response criteria in an EORTC phase II clinical trial investigating ET-743 in advanced soft tissue sarcoma.

M. van Glabbeke, P. Therasse, J. Verweij, 2005, European journal of cancer.

Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours

J. Verweij, A. Oosterom, J. Drevs, 2003 .

Cisplatin‐based chemotherapy in advanced adenoid cystic carcinoma of the head and neck

J. Verweij, J. Schornagel, P. D. De Mulder, 1992, Head & neck.

Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group.

O. S. Nielsen, S. Rodenhuis, M. van Glabbeke, 1999, European journal of cancer.

Dose-escalation models for combination phase I trials in oncology.

M. Ratain, E. Lesaffre, J. Verweij, 2010, European journal of cancer.

Relationship between clinical parameters and pharmacokinetics of mitomycin C

J. Verweij, J. Hartigh, H. Pinedo, 2004, Journal of Cancer Research and Clinical Oncology.

Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG).

J. Blay, M. van Glabbeke, J. Verweij, 2006, European journal of cancer.

Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group

J. Verweij, M. Glabbeke, A. Oosterom, 2005, Cancer Chemotherapy and Pharmacology.

Combination of daily 4-h infusion of 5-fluorouracil and cisplatin in the treatment of advanced head and neck squamous-cell carcinoma: A South-East European Oncology Group study

J. Verweij, J. Jassem, Z. Mechl, 2004, Cancer Chemotherapy and Pharmacology.

Ifosfamide in advanced head and neck cancer. A phase II study of the Rotterdam Cooperative Head and Neck Cancer Study Group.

J. Verweij, J. Alexieva-Figusch, G. Stoter, 1988, European journal of cancer & clinical oncology.

Optimum anti-emetic therapy for cisplatin induced emesis over repeat courses: ondansetron plus dexamethasone compared with metoclopramide, dexamethasone plus lorazepam.

J. Verweij, D. Cunningham, J. Smyth, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Are 5HT3 antagonists fully cross-resistant? A pilot experience

J. Verweij, G. Stoter, R. Wit, 1993 .

Mechanism‐based models for topotecan‐induced neutropenia

J. Verweij, A. Sparreboom, R. Mathijssen, 2004, Clinical pharmacology and therapeutics.

A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin)

J. Verweij, J. Schellens, D. V. Von Hoff, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumors.

J. Verweij, A. V. van Oosterom, A. Sparreboom, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Red blood cells: a neglected compartment in topotecan pharmacokinetic analysis

J. Verweij, H. Gelderblom, A. Sparreboom, 2003, Anti-cancer drugs.

Tunnelled central venous catheters yield a low incidence of septicaemia in interleukin-2-treated patients

J. Verweij, A. Eggermont, P. Schmitz, 1997, Cancer Immunology, Immunotherapy.

Clinical pharmacokinetics of encapsulated oral 9‐aminocamptothecin in plasma and saliva

Alex Sparreboom, J. Verweij, A. Sparreboom, 1999, Clinical pharmacology and therapeutics.

Pharmacokinetic-dynamic relationship of cisplatin in vitro: simulation of an i.v. bolus and 3 h and 20 h infusion.

J. Verweij, J. Schellens, G. Stoter, 1994, British Journal of Cancer.

Clinical characteristics of severe peripheral neuropathy induced by docetaxel (Taxotere).

J Verweij, M. J. van den Bent, J. Verweij, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Interleukin 2 and interferon alpha-2a do not improve anti-tumour activity of 5-fluorouracil in advanced colorectal cancer.

J. Verweij, R. Mertelsmann, J. Primrose, 1996, British Journal of Cancer.

Dose-dense cisplatin/paclitaxel. a well-tolerated and highly effective chemotherapeutic regimen in patients with advanced ovarian cancer.

J Verweij, M. J. van den Bent, J. Verweij, 2002, European Journal of Cancer.

Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancer

J. Verweij, M. Polée, A. van der Gaast, 2002, British Journal of Cancer.

Body-Surface A rea-Based D osing D oes N ot I ncrease Accuracy o f P redicting C isplatin E xposure

J. Verweij, A. Sparreboom, W. Loos, 2013 .

A pharmacokinetic interaction study of docetaxel and cisplatin plus or minus 5-fluorouracil in the treatment of patients with recurrent or metastatic solid tumors

J. Verweij, W. Loos, J. Verweij, 2006, Cancer Chemotherapy and Pharmacology.

Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure.

J. Verweij, A. Sparreboom, M. D. de Jonge, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of an alternate dosing strategy for cisplatin in patients with extreme body surface area values.

J. Verweij, A. Sparreboom, W. Loos, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

SPECIAL ARTICLE New Guidelines to Evaluate the Response to Treatment in Solid Tumors

M. Christian, E. Eisenhauer, L. Rubinstein, 2000 .

Differential distribution and red blood cell partitioning of irinotecan and SN-38 in cancer patients

J. Verweij, A. Sparreboom, W. Loos, 2002 .

Pharmacokinetics and bioavailability of oral 9-aminocamptothecin capsules in adult patients with solid tumors.

J. Verweij, C. Punt, A. Sparreboom, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Etoposide and cisplatin in advanced esophageal cancer. A preliminary report.

J. Verweij, T. Splinter, T. Kok, 1988, Acta oncologica.

Lack of c-kit exon 11 activating mutations in c-KIT/CD117-positive SCLC tumour specimens.

J. Verweij, M. D. den Bakker, H. Burger, 2003, European journal of cancer.

Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumours.

M. Piccart, J. Wanders, J. Verweij, 2002, European journal of cancer.

CYP3A4*22 Genotype and Systemic Exposure Affect Paclitaxel-Induced Neurotoxicity

E. Wiemer, J. Verweij, B. van der Holt, 2013, Clinical Cancer Research.

Phase I safety, pharmacokinetic, and pharmacodynamic study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancer.

H. Groen, E. D. de Vries, J. Verweij, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cancer Therapy

J. Verweij, G. Stoter, M. Pillay, 1989, Springer Berlin Heidelberg.

Docetaxel and paclitaxel inhibit DNA-adduct formation and intracellular accumulation of cisplatin in human leukocytes

J. Verweij, J. Schellens, W. Loos, 1996, Cancer Chemotherapy and Pharmacology.

Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: does it make a difference?

J. Verweij, A. Sparreboom, R. Mathijssen, 2007, The oncologist.

Phase I and pharmacological study of increased dose oral topotecan in combination with intravenous cisplatin.

J. Verweij, A. Sparreboom, M. D. de Jonge, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Determining the best dose for the individual patient.

J. Verweij, R. Mathijssen, W. Loos, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I and pharmacologic study of liposomal lurtotecan, NX 211: urinary excretion predicts hematologic toxicity.

H. Groen, E. D. de Vries, J. Verweij, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I pharmacokinetic and sequence finding study of the combination of docetaxel and methotrexate in patients with solid tumours.

J. Verweij, A. Sparreboom, W. Loos, 2002, European journal of cancer.

Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer.

A. Harris, J. Foekens, J. Wood, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I and pharmacological study of weekly administration of the polyamine synthesis inhibitor SAM 486A (CGP 48 664) in patients with solid tumors. European Organization for Research and Treatment of Cancer Early Clinical Studies Group.

J. Wanders, J. Verweij, L. Denis, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Effect of food on the pharmacokinetics of oral MMI270B (CGS 27023A), a novel matrix metalloproteinase inhibitor.

A. Harris, J. Verweij, A. Sparreboom, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

A prolonged methoxymorpholino doxorubicin (PNU-152243 or MMRDX) infusion schedule in patients with solid tumours: a phase 1 and pharmacokinetic study

H. Groen, J. Verweij, A. V. van Oosterom, 2000, British Journal of Cancer.

The polyamine synthesis inhibitor SAM486A in combination with 5-FU/LV in metastatic colorectal cancer (MCC): results of a phase I and pharmacokinetic study

J. Ledermann, J. Verweij, J. Bridgewater, 2000 .

Phase I and pharmacologic study of BMS-181174 given as a 6 h infusion every 4 weeks to patients with advanced solid tumors.

J. Verweij, J. Schellens, G. Stoter, 1999, Anti-cancer drugs.

Mitomycin C is an inactive drug in the third-line treatment of hormone and chemotherapy refractory breast cancer.

J. Verweij, W. van Putten, G. Stoter, 1987, European journal of cancer & clinical oncology.

Phase I and pharmacokinetic study of DE-310 in patients with advanced solid tumors.

J. Wanders, J. Verweij, A. Sparreboom, 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

Structural identification and biological activity of 7-methyl-10,11-ethylenedioxy-20(S)-camptothecin, a photodegradant of lurtotecan.

J. Verweij, A. Sparreboom, P. de Bruijn, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Review of phase I clinical studies with topotecan.

J. Verweij, E. Rowinsky, 1997, Seminars in oncology.

A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours

J. Verweij, M. D. de Jonge, J. D. de Bono, 2007, British Journal of Cancer.

Biliary Excretion of Imatinib and Its Active Metabolite CGP74588 During Severe Hepatic Dysfunction

S. Sleijfer, J. Verweij, G. Schiavon, 2012, Journal of clinical pharmacology.

Adverse effect on bone marrow protection of prechemotherapy granulocyte colony-stimulating factor support.

C. Seynaeve, J. Verweij, M. Bontenbal, 1996, Journal of the National Cancer Institute.

A phase I/II study of multicyclic dose-intensive chemotherapy supported with G-CSF, or G-CSF and haematopoietic progenitor cells in whole blood, in two consecutive cohorts of patients.

J. Verweij, C. Lamers, P. Schmitz, 1998, British Journal of Cancer.

Phase II study of edatrexate in chemotherapy-naive patients with metastatic breast cancer.

J. Verweij, J. Schornagel, A. de Graeff, 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

Toxic dermatitis induced by 10‐ethyl‐10‐deazaaminopterin (10‐EdAM), a novel antifolate

J. Verweij, J. Schornagel, F. Cognetti, 1990, Cancer.

Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer.

J. Verweij, H. V. van Doorn, D. ten Bokkel Huinink, 2014, European journal of cancer.

STI571: a magic bullet?

J. Verweij, A. V. van Oosterom, I. Judson, 2001, European journal of cancer.

Drug Transporters and Imatinib Treatment: Implications for Clinical Practice

E. Wiemer, J. Verweij, G. Schiavon, 2010, Clinical Cancer Research.

Medicinal cannabis in oncology.

R. Herings, J. Verweij, R. Mathijssen, 2007, European journal of cancer.

Clinical cancer research 2001: new agents and therapies.

J. Verweij, E. de Vries, 2001, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

P3-115: Erlotinib (Tarcevar) “dosing–to–rash”: characterization of skin toxicity from a pilot phase II intra–patient dose–escalation study of E in previously treated patients with advanced non–small cell lung cancer (NSCLC)

J. Verweij, K. Papadopoulos, M. Mita, 2007 .

Docetaxel and ifosfamide in patients with advanced solid tumors: results of a phase I study.

J. Verweij, A. V. van Oosterom, J. Schellens, 1998, Seminars in oncology.

Chemotherapy administration and data collection in an EORTC collaborative group--can we trust the results?

J. Verweij, A. V. van Oosterom, W. Steward, 1993, European journal of cancer.

The venotonic drug hydroxyethylrutosiden does not prevent or reduce docetaxel-induced fluid retention: results of a comparative study

J. Verweij, W. van Putten, G. Stoter, 1999, Cancer Chemotherapy and Pharmacology.

Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.

J. Bloem, J. Verweij, J. Nortier, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study of gefitinib for patients with advanced HER-1 expressing synovial sarcoma refractory to doxorubicin-containing regimens.

J. Blay, M. van Glabbeke, J. Verweij, 2008, The oncologist.

New drugs for the treatment of sarcomas.

J. Verweij, A. Oosterom, A. V. van Oosterom, 1995, Hematology/oncology clinics of North America.

13LBA Improved overall survival by adding regional hyperthermia to neo-adjuvant chemotherapy in patients with localized high-risk soft tissue sarcoma (HR-STS): Long-term outcomes of the EORTC 62961/ESHO randomized phase III study

Ulrich Mansmann, Claus Belka, Peter Hohenberger, 2015 .

Medicinal cannabis in oncology practice: still a bridge too far?

J. Verweij, L. van Zuylen, A. Sparreboom, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase I Pharmacokinetic and Pharmacodynamic Study of CHR-3996, an Oral Class I Selective Histone Deacetylase Inhibitor in Refractory Solid Tumors

J. Verweij, U. Banerji, M. Garrett, 2012, Clinical Cancer Research.

Lifestyle habits as a contributor to anti-cancer treatment failure.

J. Verweij, A. Sparreboom, R. Mathijssen, 2008, European journal of cancer.

Comparison of ethanol plasma-protein precipitation with plasma ultrafiltration and trichloroacetic acid protein precipitation for the measurement of unbound platinum concentrations

J. Verweij, J. Schellens, G. Stoter, 1996, Cancer Chemotherapy and Pharmacology.

Innovation in oncology clinical trial design.

F. Bretz, I. Radtke, F. Bretz, 2019, Cancer treatment reviews.

Optimal control of acute cisplatin-induced emesis.

J. Verweij, P. D. De Mulder, R. de Wit, 1996, Oncology.

Irinotecan-induced central nervous system toxicity. Report on two cases and review of the literature

S. Sleijfer, J. Verweij, P. Hamberg, 2008, Acta oncologica.

Study of a NewNucleosideAnalogue , OSI-7836 , Using TwoAdministration Schedules in Patientswith Advanced SolidMalignancies

J. Verweij, I. Judson, S. Kaye, 2006 .

High-dose chemotherapy in adult sarcomas: no standard yet.

C. Seynaeve, J. Verweij, 1999, Seminars in oncology.

Outcome of patients with advanced gastro-intestinal stromal tumors (GIST) crossing over to a daily imatinib dose of 800mg (HD) after progression on 400mg (LD) - an international, intergroup study of the EORTC, ISG and AGITG.

J. Blay, M. van Glabbeke, J. Verweij, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

S. Sleijfer, S. Litière, J. Verweij, 2014 .

Unequal Access to Newly Registered Cancer Drugs Leads to Potential Loss of Life-Years in Europe

J. Verweij, C. U. Uyl‐de Groot, M. Krol, 2020, Cancers.

Clinical and immunopathological results of a phase II study of perilymphatically injected recombinant interleukin-2 in locally far advanced, nonpretreated head and neck squamous cell carcinoma.

P. van den Broek, J. Verweij, J. Schornagel, 1991, Journal of immunotherapy : official journal of the Society for Biological Therapy.

Evaluation of CYP3A activity as a predictive covariate for docetaxel clearance.

J. Verweij, M. Carducci, H. Gelderblom, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sensitive isocratic high-performance liquid chromatographic determination of a novel indoloquinone cytotoxic drug (EO9) in human plasma and urine.

J. Verweij, J. Beijnen, W. Loos, 1993, Journal of chromatography.

Novel statistical analysis of long-term survival to account for crossover in a phase III trial of sunitinib (SU) vs. placebo (PL) in advanced GIST after imatinib (IM) failure

Patrick Schöffski, Paolo G. Casali, G. Demetri, 2008 .

Inter-relationships of paclitaxel disposition, infusion duration and Cremophor EL kinetics in cancer patients

J Verweij, J. Verweij, L. van Zuylen, 2000, Anti-cancer drugs.

Impact of pazopanib on docetaxel exposure: results of a phase I combination study with two different docetaxel schedules

S. Sleijfer, J. Verweij, P. Hamberg, 2014, Cancer Chemotherapy and Pharmacology.

Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study

S. Sleijfer, E. D. de Vries, J. Verweij, 2009, Clinical Cancer Research.

MicroRNA response to hypoxic stress in soft tissue sarcoma cells: microRNA mediated regulation of HIF3α

S. Sleijfer, E. Wiemer, J. Verweij, 2014, BMC Cancer.

A Phase I study of taxotere (T) and gemzar (G) in patients with advanced solid tumors: impact of drug sequence and feasibility

J. Verweij, A. Oosterom, H. Dumez, 1999 .

A phase II study of pirarubicin in patients with advanced recurrent head and neck squamous cell carcinoma

J. Verweij, J. Schornagel, F. Cognetti, 2004, Cancer Chemotherapy and Pharmacology.

Phase I study of the aurora kinases (AKs) inhibitor PHA-739358 administered as a 6 and 3-h IV infusion on Days 1, 8, 15 every 4 wks in patients with advanced solid tumors

Maurizio Rocchetti, J. Verweij, J. Nortier, 2008 .

Effect of cigarette smoking on pharmacokinetics, safety and efficacy of imatinib: a study based on data of the Soft Tissue and Bone Sarcoma Group of the EORTC

J. Blay, J. Verweij, M. Glabbeke, 2009 .

Effect of Cigarette Smoking on Imatinib in Patients in the Soft Tissue and Bone Sarcoma Group of the EORTC

J. Blay, M. van Glabbeke, J. Verweij, 2008, Clinical Cancer Research.

The place of chemotherapy in the management of soft tissue sarcoma: experiences of the EORTC Soft Tissue and Bone Sarcoma Group.

J. Verweij, A. Santoro, H. Mouridsen, 1989, Clinical oncology (Royal College of Radiologists (Great Britain)).

Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib.

J. Verweij, H. Joensuu, R. Maki, 2015, European journal of cancer.

Phase I trial with weekly EO9, a novel bioreductive alkylating indoloquinone, by the EORTC Early Clinical Study Group (ECSG)

S. Aamdal, J. Wanders, J. Verweij, 2000, Cancer Chemotherapy and Pharmacology.

Clinical studies with EO9, a new indoloquinone bioreductive alkylating cytotoxic agent. EORTC Early Clinical Trials Group.

S. Aamdal, J. Verweij, J. Schellens, 1994, Oncology research.

Short communication A phase II study of pirarubicin in patients with advanced recurrent head and neck squamous cell carcinoma

J. Verweij, J. Schornagel, F. Cognetti, 1994 .

Induction Chemotherapy with Cisplatin and Continuous Infusion 5‐Fluorouracil in Locally Far‐Advanced Head and Neck Cancer

G. Snow, J. Verweij, J. Schornagel, 1989, American Journal of Clinical Oncology.

Docetaxel: an interesting new drug for the treatment of head and neck cancers and soft tissue sarcomas

J. Verweij, 1995, Anti-cancer drugs.

Experience with independent radiological review during a topotecan trial in ovarian cancer.

M. Gore, S. Gwyther, J. Verweij, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Etoposide for soft tissue sarcomas: fact or fiction.

J. Verweij, 1997, European journal of cancer.

Phase II study of oral administration of etoposide for patients with well- and moderately-differentiated adenocarcinomas of unknown primary site.

J. Verweij, S. Henzen‐Logmans, A. van der Gaast, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

Effects of methimazole on the elimination of irinotecan

E. Wiemer, J. Verweij, J. Schellens, 2010, Cancer Chemotherapy and Pharmacology.

Zeniplatin in advanced malignant melanoma and renal cancer: phase II studies with unexpected nephrotoxicity

S. Aamdal, J. Wanders, J. Verweij, 1997, Cancer Chemotherapy and Pharmacology.

Phase I and pharmacokinetic study of brostallicin (PNU-166196), a new DNA minor-groove binder, administered intravenously every 3 weeks to adult patients with metastatic cancer.

J. Verweij, A. Sparreboom, M. D. de Jonge, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I and Pharmacokinetic Study of Brostallicin ( PNU-166196 ) , a New DNA Minor-Groove Binder , Administered Intravenously Every 3 Weeks to Adult Patients with Metastatic Cancer 1

J. Verweij, A. Sparreboom, F. Fiorentini, 2003 .

Trial Methodology in Soft Tissue Sarcomas; the ‘One Plus One is Three or Zero’ Phenomenon

S. Sleijfer, J. Verweij, 2008, Oncology Research and Treatment.

A phase II study of ET-743/trabectedin ('Yondelis') for patients with advanced gastrointestinal stromal tumours.

J. Blay, M. van Glabbeke, C. Seynaeve, 2004, European journal of cancer.

Alveolar Soft Part Sarcoma: Should We Be Targeting the Tumor or Targeting the Vasculature?

J. Verweij, 2012, Oncology Research and Treatment.

Phase I study of Carzelesin (U-80,244) given (4-weekly) by intravenous bolus schedule

M. Piccart, J. Wanders, J. Verweij, 1999, British Journal of Cancer.

Distribution and prognostic value of histopathologic data and immunohistochemical markers in gastrointestinal stromal tumours (GISTs): An analysis of the EORTC phase III trial of treatment of metastatic GISTs with imatinib mesylate.

J. Blay, F. Collin, M. van Glabbeke, 2008, European journal of cancer.

Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre.

C. Seynaeve, J. Verweij, M. Bontenbal, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Population Pharmacokinetics/Toxicodynamics (PK/TD) Relationship of SAM486A in Phase I Studies in Patients with Advanced Cancers

J. Verweij, Honghui Zhou, R. Capdeville, 2000, Journal of clinical pharmacology.

The impact of drug administration sequence and pharmacokinetic interaction in a phase I study of the combination of docetaxel and gemcitabine in patients with advanced solid tumors

M. Highley, J. Verweij, A. Planting, 2002, Anti-cancer drugs.

Phase I, safety, pharmacokinetic and biomarker study of BAY 57-9352, an oral VEGFR-2 inhibitor, in a continuous schedule in patients with advanced solid tumors.

J. Verweij, H. Gelderblom, D. Voliotis, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Regional hyperthermia (RHT) improves response and survival when combined with systemic chemotherapy in the management of locally advanced, high grade soft tissue sarcomas (STS) of the extremities, the body wall and the abdomen: A phase III randomised pros

J. Blay, W. Hiddemann, P. Wust, 2007 .

Broad phase II and pharmacokinetic study of methoxy-morpholino doxorubicin (FCE 23762-MMRDX) in non-small-cell lung cancer, renal cancer and other solid tumour patients.

H. Groen, J. Verweij, A. V. van Oosterom, 1998, British Journal of Cancer.

A phase Ib study of pertuzumab (P), a recombinant humanized antibody to HER2, and docetaxel (D) in patients (pts) with advanced solid tumors

J. Verweij, J. Bono, L. Pronk, 2005 .

The use of oral cytotoxic and cytostatic drugs in cancer treatment.

J. Verweij, A. Sparreboom, M. D. de Jonge, 2002, European journal of cancer.

Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albumin

D. Lacombe, J. Verweij, J. Schellens, 2012, British Journal of Cancer.

The effect of baseline morphology and its change during treatment on the accuracy of Response Evaluation Criteria in Solid Tumours in assessment of liver metastases.

S. Sleijfer, J. Verweij, G. Krestin, 2014, European Journal of Cancer.

QTc prolongation and/or oncology drug development: who's in danger?

J. Verweij, M. D. de Jonge, 2008, European journal of cancer.

Risk assessment of early progression among 213 pts with high-risk soft tissue sarcomas (HR-STS) treated with neoadjuvant chemotherapy ± regional hyperthermia: EORTC 62961/ESHO-RHT 95 intergroup phase III study

W. Hiddemann, P. Wust, J. Verweij, 2005 .

Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. The EORTC Soft Tissue and Bone Sarcoma Group.

J. Verweij, A. Santoro, H. Mouridsen, 1990, European journal of cancer.

Absence of interaction between furosemide and mitomycin C

J. Verweij, H. Pinedo, S. Kerpel-Fronius, 2004, Cancer Chemotherapy and Pharmacology.

The benefit of clinical benefit: a European perspective.

J. Verweij, 1996, Annals of Oncology.

A phase II study of high dose ifosfamide in metastatic colorectal cancer.

J. Verweij, G. Stoter, A. Hoff, 1989, European journal of cancer & clinical oncology.

Environmental and Genetic Factors Affecting Transport of Imatinib by OATP1A2

R. Kim, J. Verweij, A. Sparreboom, 2011, Clinical pharmacology and therapeutics.

Danusertib, an aurora kinase inhibitor

J. Verweij, R. Mathijssen, M. D. de Jonge, 2012, Expert opinion on investigational drugs.

Mechanisms of Action of Cancer Chemotherapeutic Agents: Antitumour Antibiotics

J. Verweij, A. Sparreboom, K. Nooter, 2005 .

A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group.

M. Piccart, J. Wanders, J. Verweij, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Influence of medicinal cannabis (MC) on the pharmacokinetics (PK) of docetaxel (DOC) and irinotecan (CPT-11)

J. Verweij, A. Sparreboom, R. Mathijssen, 2005 .

11 New response evaluation criteria in solid tumors: RECIST GUIDELINE VERSION 1.1

E. Eisenhauer, J. Verweij, 2009 .

Phase I studies of drug combinations.

J. Verweij, S. Cannistra, M. Disis, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Correction: A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation.

A. Tolcher, J. Verweij, P. LoRusso, 2022, Clinical Cancer Research.

Docetaxel and cisplatin in head and neck cancer.

J. Wanders, J. Verweij, P. Fumoleau, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

The future of drug development? Seeking evidence of activity of novel drugs in small groups of patients.

S. Sleijfer, J. Verweij, K. Ballman, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I study with the agonistic TRAIL-R1 antibody, mapatumumab, in combination with gemcitabine and cisplatin

S. Sleijfer, J. Verweij, J. Gietema, 2008 .

Outcome of patients (pts) with PDGFRAD842V mutant gastrointestinal stromal tumor (GIST) treated with imatinib (IM) for advanced disease.

J. Blay, J. Verweij, M. Debiec‐Rychter, 2010 .

Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy.

J. Blay, S. Rodenhuis, G. Demetri, 2013 .

Cancer clinical trial outcomes: any progress in tumour-size assessment?

E. Eisenhauer, P. Therasse, J. Verweij, 2009, European journal of cancer.

Chemotherapy: Adjuvant chemotherapy in older patients with breast cancer

S. Sleijfer, A. Jager, J. Verweij, 2009, Nature Reviews Clinical Oncology.

Phase I and Pharmacokinetic Study of the Dolastatin 10 Analogue TZT-1027, Given on Days 1 and 8 of a 3-Week Cycle in Patients with Advanced Solid Tumors

J. Wanders, J. Verweij, M. D. de Jonge, 2005, Clinical Cancer Research.

Phase I and Pharmacokinetic Study of the Dolastatin 10 Analogue TZT-1027 , Given on Days 1 and 8 of a 3-Week Cycle in Patientswith Advanced SolidTumors

J. Wanders, J. Verweij, M. D. Jonge, 2005 .

First interim report on the randomized EORTC 62961/ESHO-RHT 95 Intergroup Study (phase III) combined with regional hyperthermia (RHT) versus chemotherapy alone in the treatment of high-risk soft tissue sarcomas (HR-STS) in adults.

J. Blay, P. Wust, J. Verweij, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours.

J. Verweij, M. D. de Jonge, P. Schöffski, 2011, European journal of cancer.

Dose-finding and pharmacokinetic study of ABT-510 with gemcitabine and cisplatin in patients with advanced cancer

de Elisabeth G. E. Vries, H. Groen, J. Verweij, 2004 .

Correction: Tumor Volume as an Alternative Response Measurement for Imatinib Treated GIST Patients

S. Sleijfer, J. Verweij, G. Krestin, 2013, PLoS ONE.

Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG)

S. Aamdal, J. Wanders, J. Verweij, 2000, Cancer Chemotherapy and Pharmacology.

72 POSTER Phase I, safety, pharmacokinetic and biomarker study of telatinib (BAY 57-9352), an oral VEGFR-2 inhibitor, in a continuous schedule in patients with advanced solid tumors

J. Verweij, H. Gelderblom, P. Rajagopalan, 2006 .

Trial design for cancer (cell)-specific anticancer therapies

J. Verweij, F. Eskens, R. van Alphen, 2007, Expert opinion on therapeutic targets.

Erlotinib ‘dosing-to-rash’: a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer

A. Tolcher, J. Verweij, K. Papadopoulos, 2011, British Journal of Cancer.

Clinical trials in drug development: a minimalistic approach

J. Verweij, 2012, Current Opinion in Oncology.

Effect of FNCLCC grade 2 versus grade 3 on survival after neoadjuvant chemotherapy (NAC) plus or minus regional hyperthermia (RHT) in soft tissue sarcomas (STS): An analysis of the EORTC-ESHO Intergroup phase III study.

W. Hiddemann, U. Mansmann, J. Verweij, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The use of recombinant human granulocyte-macrophage colony-stimulating factor with combination chemotherapy in the treatment of advanced adult soft-tissue sarcomas: early results from the EORTC Soft-Tissue and Bone Sarcoma Group.

D. Crowther, J. Verweij, T. Tursz, 1993, Cancer chemotherapy and pharmacology.

Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours

J. Verweij, H. Burger, M. D. de Jonge, 2010, British Journal of Cancer.

Granisetron vs ondansetron: is it a question of duration of 5-HT3 receptor blockade?

J. Verweij, M. Aapro, A. Sparreboom, 2002, British Journal of Cancer.

A phase II study of taxotere in patients with advanced head and neck cancer

M. Piccart, J. Wanders, J. Verweij, 1993 .

A phase I/II study of combined weekly systemic cisplatin and locoregional hyperthermia in patients with previously irradiated recurrent carcinoma of the uterine cervix

J. Verweij, J. Zee, R. Wit, 1999, British Journal of Cancer.

Effects of impaired renal function on the pharmacokinetics and toxicity of i.v. ZD9331, a novel non-polyglutamated thymidylate synthase inhibitor, in adult patients with solid tumors

S. Culine, J. Verweij, J. Bonneterre, 2002, Anti-cancer drugs.

E¡ects of impaired renal function on the pharmacokinetics and toxicity of i.v. ZD9331, a novel non-polyglutamated thymidylate synthase inhibitor, in adult patients with solid tumors

S. Culine, J. Verweij, J. Bonneterre, 2002 .

Phase II study of nimustine in metastatic soft tissue sarcoma. European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.

J. Verweij, A. Santoro, P. Woll, 1991, European journal of cancer.

Is a stable disease according to RECIST criteria a real stable disease in GIST patients treated with imatinib mesylate (IM) included in the intergroup EORTC/ISG/AGITG trial?

J. Blay, J. Verweij, M. Glabbeke, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MicroRNA response to hypoxic stress in soft tissue sarcoma cells: microRNA mediated regulation of HIF3α

S. Sleijfer, E. Wiemer, J. Verweij, 2014, BMC Cancer.

Matrix metalloproteinase inhibitors: Present achievements and future prospects

J. Verweij, L. Denis, J. Verweij, 1997, Investigational new drugs.

The Price of Success: Cost‐Effectiveness of Molecularly Targeted Agents

S. Sleijfer, J. Verweij, S. Sleijfer, 2009, Clinical pharmacology and therapeutics.

Correction: Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: A Phase I Study

J. Verweij, C. Mom, C. Oldenhuis, 2009, Clinical Cancer Research.

Single-dimension CT measurements with RECIST 1.1 to evaluate liver metastases in GIST patients on imatinib (Abstract)

S. Sleijfer, J. Verweij, G. Krestin, 2012 .

Health policy: Affordability of drugs used in oncology health care

S. Sleijfer, J. Verweij, 2016, Nature Reviews Clinical Oncology.

Systematic review on the use of systemic anticancer therapy in renal-impaired gynecological cancer patients.

J. Verweij, A. Sparreboom, F. D. de Jong, 2008, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

Letter

J. Verweij, A. Sparreboom, F. D. de Jong, 2007, International Journal of Gynecologic Cancer.

Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients.

J. Verweij, J. von Pawel, U. Gatzemeier, 1998, Journal of Clinical Oncology.

Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells.

J. Verweij, J. Schellens, G. Schwartz, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I study of Carzelesin (U-80,244) given (4-weekly) by intravenous bolus schedule

M. Piccart, J. Verweij, C. Punt, 1999, British Journal of Cancer.

Short report: Phase II study of combining vinblastine and cyclosporin-A to circumvent multidrug resistance in renal cell cancer

C. Seynaeve, J. Verweij, H. Herweijer, 1991 .

The absence of influence of acetylsalicylic acid (ASA) on the transient decrease in platelet counts observed after infusion of bleomycin and vinblastine.

J. Verweij, H. Hillen, H. Pinedo, 1985, European journal of cancer & clinical oncology.

Interaction of Cisplatin with the Human Organic Cation Transporter 2

J. Verweij, A. Sparreboom, W. Loos, 2008, Clinical Cancer Research.

Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group.

J. Verweij, M. Glabbeke, M. Schlemmer, 2008, European journal of cancer.

A CYP3A4 Phenotype–Based Dosing Algorithm for Individualized Treatment of Irinotecan

E. Wiemer, J. Verweij, A. Sparreboom, 2010, Clinical Cancer Research.

Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study

S. Sleijfer, E. D. de Vries, J. Verweij, 2009, Clinical Cancer Research.

Drug transporters of platinum-based anticancer agents and their clinical significance.

E. Wiemer, J. Verweij, R. Mathijssen, 2011, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

The kinase RSK2 modulates the sensitivity of ovarian cancer cells to cisplatin.

Marijn T. M. van Jaarsveld, A. W. Boersma, E. Wiemer, 2013, European Journal of Cancer.

[The Dutch Health Council report on palliative chemotherapy: possible confusion on ideas].

J. Verweij, P. D. De Mulder, H. Pinedo, 2004, Nederlands tijdschrift voor geneeskunde.

Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.

J. Blay, C. Fisher, S. Litière, 2014, The Lancet. Oncology.

Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study.

J. Blay, W. Hiddemann, P. Wust, 2010, The Lancet. Oncology.

Therapeutic Drug Monitoring for the Individualization of Docetaxel Dosing: A Randomized Pharmacokinetic Study

J. Verweij, R. Mathijssen, P. de Bruijn, 2011, Clinical Cancer Research.

Individual patient data analysis to assess modifications to the RECIST criteria.

L. Schwartz, D. Sargent, D. Lacombe, 2009, European journal of cancer.

Subtyping soft tissue sarcomas for treatment approaches

J. Blay, J. Verweij, R. Maki, 2012 .

Outcome of Patients with Platelet-Derived Growth Factor Receptor Alpha–Mutated Gastrointestinal Stromal Tumors in the Tyrosine Kinase Inhibitor Era

J. Blay, F. Bertucci, J. Verweij, 2012, Clinical Cancer Research.

A prolonged methoxymorpholino doxorubicin (PNU-152243 or MMRDX) infusion schedule in patients with solid tumours: a phase 1 and pharmacokinetic study

J. Verweij, H. Groen, D. Uges, 2000, British Journal of Cancer.

Soft Tissue Sarcomas: New Developments in the Multidisciplinary Approach to Treatment

J. Verweij, H. Suit, H. Pinedo, 1991, Cancer Treatment and Research.

Effect of Cigarette Smoking on Imatinib in Patients in the Soft Tissue and Bone Sarcoma Group of the EORTC

J. Blay, J. Verweij, H. Guchelaar, 2008, Clinical Cancer Research.

Soft Tissue Sarcomas: Present Achievements and Future Prospects

J. Verweij, H. Suit, H. Pinedo, 1997, Cancer Treatment and Research.

A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours

J. Verweij, J. Bono, L. Pronk, 2007, British Journal of Cancer.

The difference in pharmacokinetics of mitomycin C, given either as a single agent or as a part of combination chemotherapy

J. Verweij, H. Pinedo, M. Stuurman, 2004, Journal of Cancer Research and Clinical Oncology.

Mechanism-Based P harmacokinetic M odel f or P aclitaxel

J. Verweij, M. Karlsson, L. Gianni, 2001 .

Population Pharmacokinetic Model for Cremophor EL

J. Verweij, M. Karlsson, A. Sparreboom, 2005 .

Gender-dependent pharmacokinetics of topotecan in adult patients

J. Verweij, H. Gelderblom, A. Sparreboom, 2000, Anti-cancer drugs.

The use of hematological growth factors to enable dose intensification in chemotherapy for soft tissue sarcomas

J. Verweij, G. Liem, 1994, Stem cells.

Effect of omeprazole on the pharmacokinetics and toxicities of irinotecan in cancer patients: a prospective cross-over drug-drug interaction study.

E. Wiemer, J. Verweij, R. Mathijssen, 2011, European journal of cancer.

Soft Tissue Sarcomas: Present Achievements and Future Prospects

J. Verweij, H. Suit, H. Pinedo, 1997, Cancer treatment and research.

Taxotere in advanced malignant melanoma: A fase-II trial of the eortc early clinical trials group

M. Piccart, S. Aamdal, R. Paridaens, 1993 .

Phase II study with taxotere(RP56976) in advanced soft tissue sarcomas of the adult

J. Verweij, M. Glabbeke, H. Mouridsen, 1993 .

Chemotherapy in advanced soft tissue sarcomas.

J. Verweij, H. Pinedo, C. V. van Groeningen, 1989, Cancer treatment and research.

Tumor volumes measurement (3D) versus Response Evaluation Criteria in Solid Tumors (RECIST version 1.1, 1D) and Choi criteria (C) in assessing response of gastrointestinal stromal tumors (GIST) to imatinib (IM).

S. Sleijfer, J. Verweij, G. Krestin, 2011, Journal of Clinical Oncology.

Structural identification and biological activity of 7-methyl-10,11-ethylenedioxy-20(S)-camptothecin, a photodegradant of lurtotecan.

J. Verweij, A. Sparreboom, P. de Bruijn, 2002, Clinical Cancer Research.

The relevance of microdialysis for clinical on:cology.

E. Wiemer, J. Verweij, W. Loos, 2006, Current clinical pharmacology.

Reply to F.L. Opdam et al

J. Verweij, R. Mathijssen, W. Loos, 2012 .

Patient perception of the side effects of chemotherapy; the influence of the introduction of 5TH3 antagonists

J. Verweij, G. Stoter, B. Visser, 1993 .

Phase I/II study of a short course of weekly cisplatin in patients with advanced solid tumours.

J. Verweij, G. Stoter, M. Boer-Dennert, 1993, British Journal of Cancer.

Carcinoma of unknown primary: identification of a treatable subset?

J. Verweij, S. Henzen‐Logmans, A. van der Gaast, 1990, Annals of oncology : official journal of the European Society for Medical Oncology.

Liquid chromatographic assays for DE-310, a novel camptothecin analog, and two major enzymatic products in human matrices.

J. Verweij, A. Sparreboom, P. de Bruijn, 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

5-HT3 receptor antagonists, a new approach in emesis: a review of ondansetron, granisetron and tropisetron.

C. Seynaeve, J. Verweij, P. D. De Mulder, 1991, Anti-cancer drugs.

Possible lack of full cross-resistance of 5HT3 antagonists; a pilot study

J. Verweij, G. Stoter, R. Wit, 1995, Journal of Cancer Research and Clinical Oncology.

Topoisomerase I inhibition: a new target or new missiles?

J. Verweij, J. Schellens, 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

565 Phase II studies with EO9 in breast, colorectal, gastric, pancreatic and NSCLC

J. Wanders, J. Verweij, L. Dirix, 1995 .

Corticosteroid co-medication does not reduce the incidence and severity of neurotoxicity induced by docetaxel

J. Verweij, G. Stoter, M. J. van den Bent, 1998, Anti-cancer drugs.

Confusion caused by similarity in manuscript titles.

J. Verweij, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic and predictive factors for outcome to first-line ifosfamide-containing therapy (IFM) in patients (pts) with advanced soft tissue sarcomas (STS) treated in EORTC-STBSG studies

S. Sleijfer, J. Blay, S. Rodenhuis, 2008 .

Phase II study with topotecan in colorectal cancer

J. Wanders, J. Verweij, S. Kaye, 1993 .

926 Pharmacokinetics (PK), clinical pharmacodynamics (PD) and safety of chronic oral topotecan (T), in a phase I study

J. Verweij, J. Schellens, W. Loos, 1995 .

Phase I and Pharmacokinetic Study of the Polyamine Synthesis Inhibitor SAM486A in Combination with 5-Fluorouracil/ Leucovorin in Metastatic Colorectal Cancer

J. Ledermann, J. Verweij, L. van Zuylen, 2004, Clinical Cancer Research.

27 ORAL Phase I dose escalation study of the aurora kinase inhibitor PHA-739358 administered as a 6-hour infusion on days 1, 8 and 15 every 4 weeks in patients with advanced/metastatic solid tumors

J. Verweij, J. Nortier, H. Gelderblom, 2006 .